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 While we generally eat infrequently, metabolic processes within our body tightly 
regulate blood glucose levels.  The metabolic system is comprised of various tissues, 
each of which contains specific regulatory pathways that determine the function of the 
tissue within the system.  These tissues and their localized metabolic functions, 
complement one another through inter-tissue metabolic highways to form the entire 
metabolic system.  The liver is a key control center of metabolism and thus, the 
mathematical model described in this thesis is heavily ‘liver-centric.’  Though all 
hepatocytes, or liver cells, are capable of similar metabolic functions, the rate at which 
these functions are carried out depends on the location of the hepatocytes within the liver. 
At the intracellular level, the various metabolic pathways contain many intersections.  
Though the intracellular components of the metabolic system are spatially localized, I 
assume a well-mixed cell and ignore spatial heterogeneity 
 While physiological layering is important to accurately model metabolism, the 
layering of regulation within the system is also of interest for our model.  The 
biochemical processes that make up metabolic pathways are regulated on many levels, 
such as by metabolites, hormones and enzymes, and also at a pre-protein level through 
transcription.  While the model developed here does not include all levels of metabolic 
 iv 
control it does address the need for understanding of metabolism from a multi-level 
perspective.  The main conclusions from this study are that while fats are utilized to help 
produce glucose during periods of low blood glucose levels, resulting ketone bodies are 
kept at a minimal level and that heatmaps are an effective visual tool in evaluating model 
simulations.  The enzyme circuit of the glycogen regulatory system allows for efficient 
modification of activity of enzymes to quickly increase the rate at which excess glucose 
is stored as glycogen.  Also, as blood glucose levels drop, this enzyme circuitry is 
modified so that glycogen, amino acids and fats are broken down to produce glucose so 
that blood glucose levels are stabilized.  The proposed model suggests that while fats are 
utilized in this process, ketone bodies resulting from lipolysis are kept at low levels, 
which is essential to protect the system from ketoacidosis.  A mathematical model of a 
reduced glycogen regulatory circuit was developed and compared to a model of the full 
glycogen regulatory circuit.  Though simulations of these models were similar in 
isolation, they produced different results when immersed in a contextual model which 
captured the multiple tissue environment of the metabolic system.  This method allowed 
investigation into the effects of the enzyme cascade in the glycogen regulatory system.  
Heatmaps enabled quick assessment of model simulations and were vital for obtaining an 
overall ‘fluxomic’ picture of the state of the system. 
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My initial interest in the application of mathematics to biological systems was 
inspired by an example given in one of my classes for a mathematical application to 
cancer detection.  The thought of using mathematics to further medical knowledge and 
thus help people encouraged me to work in the field of mathematical biology.  From an 
educational perspective, this is a very exciting time to work in this field of research as we 
are currently in the beginning of a great revolution of bringing together disciplines that 
have traditionally been separated.  Life does not separate itself into history, English, 
biology, mathematics, etcetera but is a continuous blend of cross-disciplinary concepts.  I 
believe that as we continue in this movement to modify education to learn using this 
connected viewpoint, we will be more successful in learning about ourselves and the 
world around us.  The challenge of investigating the metabolic system from a systems 
biology point of view through mathematical modeling is daunting but very important as 
there has been a drastic increase in the prevalence of obesity, diabetes and other concerns 
relating to metabolism.  By obtaining a better understanding of metabolic processes, 
especially during transitional feeding periods, we will have a broader knowledge base 
from which to determine effective methods for controlling diabetes and obesity as well as 
other undesirable metabolic conditions. 
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 A vast amount of biological data has been obtained through technological 
advances over the past decade.  Advances in scientific computing have allowed 
mathematical modeling to become a very useful tool in understanding this data and thus 
increasing out knowledge of particular systems.  The metabolic system is quite complex 
and though many of its components have been explored through modeling, these models 
have been investigated in isolation.  The level of glucose, the main fuel for most cells, is 
tightly regulated by the metabolic system.  Glycogen is a stored form of glucose and is 
made when there is excess glucose and degraded to make glucose during times of a 
glucose shortage.  This thesis aims to explore the mechanisms behind this synthesis and 
utilization of glycogen by connecting an isolated mathematical model of the glycogen 
regulation system to a larger model of the metabolic system. 
 
1.1 Overview of Metabolism 
The human body is a complex system that has a constant demand for energetic 
resources.  These energetic resources are made available to the body through the diet, and 
as people typically experience separate times of eating and fasting, the body must 
establish a method of using energy derived from the digestion of meals in such a way as 
 2 
to provide a constant source of fuel to meet its energetic demands.  To maintain 
continuous provision of energetic substrates, the human body has a sophisticated method 
of storing these products.  Liver glycogen, a form of transient storage for energetic 
resources, was discovered by Claude Bernard in 1857 [1] and though much is now known 
about the role of glycogen in metabolism, there is still much to be explored.  This thesis 
develops and analyzes a mathematical model of the control mechanisms that regulate the 
storage and utilization of liver glycogen. 
Food is introduced to the body mainly as a mixture of carbohydrates, proteins and 
fats which are digested in the gut to form glucose, amino acids and free fatty acids, 
respectively.  Glucose enters the liver from the gut via the hepatic portal vein and is the 
main metabolic fuel of most cells and the sole metabolic fuel for certain cells such as 
erythrocytes [2].  Blood glucose levels must be tightly regulated to ensure a constant 
provision of glucose to these cells.  Amino acids, which also enter the liver through the 
hepatic portal vein, can be used to build tissue protein or be converted to metabolites 
through transamination or the switching of amino groups from one molecule to another.  
Free fatty acids, either obtained from the diet or from biochemical conversion of excess 
dietary carbohydrates, are then stored in adipose, or fat, tissue. 
During feeding, glucose is plentiful and there is a net conversion of glucose into 
glycogen for short term storage and fats for long term storage.  (Figure 1.1.)  As the 
system transitions from a feeding state into a post-absorptive state, blood glucose levels 
decrease and the body switches from storing glucose to utilizing glycogen and fat to 
make glucose.  (Figure 1.2.)  Specific mechanisms which facilitate this directional change 
of net flux are discussed later.  These changes within the system in response to a loss of 
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glucose input create interesting dynamics due to the nonlinear feedback mechanisms used 
to maintain homeostasis.  Thus, investigations of this thesis focus on regulatory 














Figure 1.1  Sources of Blood Glucose During a Meal.  Food is digested in the 
gut to form proteins, carbohydrates and fats.  These products are converted to 
amino acids, glucose and free fatty acids, respectively.  Glucose is taken up by 
all tissues while amino acids are mainly taken up by the muscle and free fatty 











Figure 1.2  Sources of Blood Glucose During Fasting.  Fluxes denoted by solid 




1.2 The Problem 
Two of the main regulators of metabolic pathways are the hormones insulin and 
glucagon, secreted from the beta cells and alpha cells of the pancreas, respectively.  It has 
been well documented that calcium oscillations lead to oscillations in the secretion of 
insulin [3, 4] and these oscillations, in turn, create oscillatory dynamics in blood glucose 
concentrations.  Though a number of mathematical models have been developed to 
capture the oscillatory features of glucose, insulin and glucagon [5-8], none of these 
include a detailed description of the feedback regulation of insulin and glucagon on blood 
glucose levels.  Through intermediary signals, these two hormones regulate multiple 
metabolic pathways [9, 10].  Insulin and glucagon also regulate levels of the second 
messenger cyclic adenosine monophosphate (cAMP) which in turn regulates multiple 
metabolic processes.  The mechanism by which oscillations in blood glucose levels occur 
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as a result of oscillations in insulin secretion have not been determined.  The model 
introduced in this thesis aims to explain a possible cause for the resulting behavior of 
blood glucose levels in response to dynamical changes in the regulatory components 
during the transition from a fed to a fasted state. 
 Some metabolic pathways, such as glycogen synthesis and degradation, are 
irreversible due to processes that are highly favored to be unidirectional but function in 
an opposite manner.  Glycogen synthesis will convert a molecule of glucose 6-phosphate 
into glycogen while glycogen degradation takes glycogen and converts it into glucose 6-
phosphate [10].  When both pathways are active at the same time, a phenomenon known 
as futile cycling occurs [11, 12].  While the exact effects of futile cycling on the 
metabolic system are unknown, it has been observed with glycogen synthesis and 
degradation during a fasted state.  It is hypothesized that the amount of futile cycling 
present during the fasting period determines the response time, the time in which the 
system returns to a fed homeostatic state, once food is reintroduced to the system.   
 
1.3 The Purpose 
It is estimated that around 4% of the American population had diabetes in 2000 
and that this will increase to around 7% by 2050 [13].  Diabetes has long been around and 
continues to be an expensive health issue.  Symptoms of this disease include an excess of 
sugar in the urine due to the high levels of glucose in the blood and the inability of the 
metabolic system to regulate these glucose levels.  Type I diabetes occurs when the beta 
cells of the pancreas are unable to produce insulin resulting in compromised secretion of 
this key regulatory hormone.  Type II diabetes occurs when insulin secretion is normal 
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but the signaling of this hormone is dysfunctional leading to compromised regulation by 
this hormone.  A better understanding of the regulatory mechanisms of insulin on the 
enzyme cascade for storage and utilization of glycogen can help build a better 





Framework of Metabolism 
 
Metabolism can be defined as the collection of biochemical processes by which 
digested food is converted into energy through pathways that contain both anabolic and 
catabolic processes [10].  The metabolic system is very complex and so to become 
familiar with this system, I first look at an overview of main metabolic pathways.  After 
looking at different tissues which make up this framework, I discuss the main metabolic 
pathways in more detail to better understand the functions of the various tissues and how 
they work together to form the metabolic system. 
 
2.1 Overview of Metabolic Pathways 
 It is important to understand the functionality of metabolic pathways before 
discussing the main tissues involved with metabolism.  For modeling purposes, I only 
focus on select pathways but in this section I take a brief glance at pathways not included 
in our model as well as those I chose as key metabolic pathways.  Table 2.1 provides a 
list of the various metabolic pathways and their main functions.  It is important to note 
that while we speak of separate pathways, the metabolic system is in fact not so neatly 
separated in reality but is a collection of numerous messy reactions constricted within a 
small area of a cell.  For simplicity, I assume that once a molecule has entered a reaction 
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that the molecule is committed to completing this reaction.  We also assume no 
metabolite concentration is in an intermediate state of these biochemical processes.   
 
Pathway Function 
Glycolysis breakdown of glucose to pyruvate which then can release 
ATP by being converted to lactate (anaerobic glycolysis) or 
being converted to acetyl-CoA and entering the TCA cycle 
(aerobic glycolysis) 
Gluconeogenesis Conversion of amino acids to glucose 
TCA cycle Set of biochemical reactions common to glucose, amino acid 
and fat metabolism, an intersection for these pathways.  
Under aerobic conditions, factors released during reactions 
of the TCA cycle enter oxidative phosphorylation resulting 
in ATP synthesis 
Glycogenesis Glucose is converted to glycogen, a transient storage form of 
glucose 
Glycogenolysis Glycogen is converted to glucose 
Lipogenesis Biosynthesis of fats from excess glucose 
Lipolysis Breakdown of fats, most products from this pathway are 
unable to enter gluconeogenesis but are beneficial in 
producing ATP via oxidative phosphorylation 
Ketogenesis Synthesis of ketone bodies, a byproduct of lipolysis and 
alternate metabolic fuel for some tissues such as muscle and 
brain 
Table 2.1.  Overview of Metabolic Pathways.  These are the metabolic pathways 
considered for the model proposed in this thesis. 
 
 With the exception of two pathways listed in the table, the model is concerned 
with paired pathways which results in the production and degradation of certain 
metabolites.  Glycolysis and gluconeogenesis describes the formation and conversion of 
glucose; glycogenesis and glycogenolysis are the pathways by which glycogen is 
produced and degraded; lipogenesis and lipolysis are the pathways by which fats are built 
up and broken down.  Though many of the biochemical reactions of each pathway are 
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reversible, some of them are not requiring different enzymes for the synthesis and 
degradation of these metabolites.  The differences within these pathways will be 
discussed in Section 2.3.  The two pathways which do not have opposite functions are the 
TCA cycle and ketogenesis. 
 
 
2.2 Physiology of the Metabolic System 
 Now that we are somewhat familiar with the functions of metabolic pathways, we 
will look at the various tissues involved in the metabolic system.  The model contains 
four of the main metabolic tissues:  liver, blood, muscle and fat.  Table 2.2 lists these 
tissues along with other tissues and the metabolic pathways found within each tissue. 
 
Tissue Pathways Present 
Liver Glycolysis, gluconeogenesis, glycogenesis, glycogenolysis, TCA 
cycle, lipogenesis, lipolysis, ketogenesis 
Blood None 
Muscle Glycolysis, glycogenesis, glycogenolysis, TCA cycle, lipolysis, ketone 
body utilization 
Fat Glycolysis, TCA cycle, lipogenesis, lipolysis 
*Kidney Glycolysis, gluconeogenesis, TCA cycle 
*Brain Glycolysis, TCA cycle, lipolysis, ketone body utilization 
*Heart Glycolysis, TCA cycle, lipolysis, ketone body utilization 
*Erythrocytes Glycolysis (anaerobic) 
Table 2.2.  Tissue-Specific Metabolic Pathways.  Tissues denoted by * are not 






 As Table 2.2 shows, hepatic cells are capable of most metabolic pathways.  Liver 
and muscle tissues are also the site of major stores of glycogen.  The regulation of 
glycogenesis and glycogenolysis in the liver is such that hepatic glycogen is a main 
source of glucose during times of fasting, allowing hepatic glycogen to eventually be 
converted to metabolic fuel for other tissues.  Erythrocytes, among other cells, are solely 
reliant on glucose as they lack the presence of the TCA cycle needed to use fats or ketone 
bodies as alternative fuels.  Muscle glycogen is primarily used to provide energy for the 
cell in which the glycogen is stored.  The role of hepatic glycogen, to be used for glucose 
production for the liver and other tissues, and the ability of liver to process amino acid 
and fat metabolism help make the liver the control center of the metabolic system. 
 
2.2.2 Blood 
Though biochemical processes occur in the blood we assume that the blood is 
simply a transport vehicle for metabolites. 
 
2.2.3 Fat 
Fat is useful to the body in many ways, including regulating body temperature, 
insulating body organs and storage of important excess metabolic fuels.  A certain 
amount of fat is necessary for optimal functioning of the body but can start to have 
negative effects when there is too much of it.  Excess dietary glucose is transported 
directly to fat tissue and is also converted into free fatty acids within the liver and then 
transferred to fat tissue for storage.  When glucose levels drop, these stored fats are then 
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transported back to the liver and enter lipolysis providing substrate for the TCA cycle 
within the liver as well as increasing the rate at which gluconeogenesis occurs resulting in 
glucose being released from the liver to the blood.  Fats can also be transported to other 
tissues with mitochondria capable of lipolysis and directly provide energy. 
 
2.2.4 Muscle 
 Though muscle has its own store of glycogen, this store is conserved for when a 
sudden demand for energy occurs.  Muscle utilizes glucose as substrate of glycogen 
storage and also for immediate metabolic fuel.  Muscle tissue is capable of lipolysis and 
contains the TCA cycle so is able to process alternate metabolic fuels during a fasted 
state.  This preserves blood glucose levels for tissues that are incapable of switching to 
alternate fuels.  Muscle cells lack an enzyme required for making glucose from both 
gluconeogenesis and glycogenolysis.  Assistance from muscle tissue in regulating blood 
glucose comes from using less blood glucose during fasting and also from providing 
substrate for gluconeogenesis to the liver through the Cori cycle [9, 10]. 
 
2.2.5 Others 
All tissues affect and are affected by the regulation of metabolism in some way.  
Other tissues that contribute a significant amount of interaction with the metabolic system 
are heart, brain, kidney and pancreatic tissues.  For simplification purposes, these do not 




2.3 Select Metabolic Pathways 
 Though this thesis focuses on the fate of glucose as an energy source, the 
proposed mathematical model is capable of investigating other forms of fuel and this 
concept is included in the chapter addressing future work.  The main result of a functional 
metabolic system is providing the correct supply of energy to the system at each moment 
in time.  As discussed earlier, in order for this to occur, blood glucose levels must be 
tightly regulated within a set concentration threshold.  This section describes the main 
metabolic pathways that help regulate these blood glucose levels. 
 
2.3.1 Glycolysis 
Glycolysis is the pathway by which glucose is converted into pyruvate which then 
can enter exergonic processes, releasing energy through either aerobic or anaerobic 
means [9, 10].  Glycolysis and the anaerobic (oxygen independent) pathway of producing 
energy are found in the cytosol of all cells whereas the machinery required to aerobically 
produce energy requires the presence of mitochondria.  Figure 2.1 shows the complete 
pathway from glucose to pyruvate and also includes the anaerobic step from pyruvate to 
lactate. 
Though including each reaction of the metabolic system in a mathematical model 
would result in a comprehensive model, the analysis of such an extensive system would 
be very challenging.  To simplify the analysis of the contextual or whole-physiological 
model, only those reactions which limit the flux through the pathways of interest are 
























Figure 2.1.  The Complete Pathway of Glycolysis.  Enzymes catalyzing specific 
reactions are denoted in boxes next to the arrow of each corresponding reaction.  
Enzymes with dashed outlines are specific to glycolysis while those with 
outlined in solid are also found in gluconeogenesis.  Abbreviations are as 
follows:  HK, hexokinase; GK, glucokinase; PHI, phosphokexose isomerase; 
PFK, phosphofructokinase; ALD, aldolase; PTI, phosphotriose isomerase; GPD, 
glyceraldehyde-3-phosphate dehydrogenase; PGK, phosphoglycerate kinase; 
PGM, phosphoglycerate mutase; ENO, enolase; PK, pyruvate kinase; LDH, 
lactate dehydrogenase. 
 
that detail the specific steps of the pathway.  A reduction of these pathways in Chapter 4 
is given in context of the mathematical model developed to describe their behavior.  
Table 2.3, which corresponds with Figure 2.1, lists the detailed reactions of glycolysis. 
 In many of the reactions listed in this thesis and other metabolic and non-
metabolic reactions not listed, ATP exists as a cofactor.  ATP, the main energy carrying 
compound for the body, is the result of glucose metabolism.  In Figure 2.1, anaerobic 
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ENZYME  (Enzyme Commission number and name) 
     REACTION 
HK, GK  (EC 2.7.1.1  hexokinase, EC 2.7.1.2  glucokinase) 
     ATP + glucose = ADP + glucose 6-phosphate 
PHI  (EC 5.3.1.9  phosphohexose isomerase) 
     glucose 6-phosphate = fructose 6-phosphate 
PFK  (EC 2.7.1.11  phosphofructose kinase) 
     ATP + fructose 6-phosphate = ADP + fructose 1,6-bisphosphate 
ALD  (EC 4.1.2.13  aldolase) 
     fructose 1,6-bisphosphate = glycerone phosphate + glyceraldehyde 3-phosphate 
PTI  (EC 5.3.1.1  phosphotriose isomerase) 
     glycerone phosphate  = glyceraldehyde 3-phosphate 
GPD  (EC 1.2.1.12  glyceraldehyde 3-phosphate dehydrogenase) 
     glyceraldehyde 3-phosphate + phosphate + NAD+ = 1,3-bisphosphoglycerate + NADH + H+ 
PGK  (EC 2.7.2.3  phosphoglycerate kinase) 
     ADP + 1,3-bisphosphoglycerate = ATP + 3-phospho-glycerate 
PGM  (EC 5.4.2.1  phosphoglycerate mutase) 
     3-phospho-glycerate  = 2-phospho-glycerate 
ENO  (EC 4.2.1.11  enolase) 
     2-phospho-glycerate = phosphoenolpyruvate + H2O 
PK  (EC 2.7.1.40  pyruvate kinase) 
     ADP + phosphoenolpyruvate = ATP + pyruvate 
LDH  (EC 1.1.1.27  lactate dehydrogenase) 
     pyruvate + NADH + H+ = lactate + NAD+ 
Table 2.3.  Reactions of the Pathway of Glycolysis.  Enzyme abbreviations 
correspond with those in Figure 2.1.  For each reaction, the full enzyme name 
and Enzyme Commission number is listed as well as the full reaction with all 
substrates, products and cofactors. 
 
glycolysis was included, that being from pyruvate to lactate.  In Table 2.3, we see that the 
reaction catalyzed by lactate dehydrogenase, LDH, results in a molecule of NAD+.  This 
NAD+ can act as substrate for the reaction catalyzed by glyceraldehyde 3-phosphate 
dehydrogenase, GPD, thus encouraging glycolysis to continue.  Anaerobic glycolysis 
provides a net gain of two ATP molecules.  Due to aldolase splitting fructose 1,6-
bisphosphate into two separate compounds and phosphotriose isomerase converting one 
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of these compounds into the other, we see the stoichiometry of  2:1 for glucose: 
glyceraldehyde 3-phosphate.  So though the glucokinase and phosphofructose kinase reactions use 
up one molecule each of ATP, PGK and PK both release one ATP resulting in 2 ATP molecules 
used to 4 ATP molecules released, or a net gain of 2 ATP molecules [10]. 
 Anaerobic glycolysis is unable to keep up with the normal energetic demands of the body 
for long periods and we will see it is much more efficient to release energy through aerobic 





























Figure 2.2.  The Tricarboxylic Acid (TCA) Cycle.  Enzymes catalyzing specific 
reactions are denoted in boxes next to the arrow of each corresponding reaction.  
Abbreviations are as follows:  PC, pyruvate carboxylase; PDH, pyruvate 
dehydrogenase; CS, citrate synthase; ACT, aconitase; IDH, isocitrate 
dehydrogenase; KDH, α-ketoglutarate dehydrogenase; STK, succinate 
thiokinase; SDK, succinate dehydrogenase; FMS, fumarase; MDH, malate 
dehydrogenase; MS, malate shuttle. 
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production and is usually the most prominent method unless there is a sudden drop of oxygen 
concentration, such as during extreme exercise.  Aerobic glycolysis occurs in the mitochondria and  
requires the presence of the tricarboxylic acid (TCA) cycle machinery.  In Figure 2.1, an 
arrow shows continued metabolism of pyruvate through oxidation.  This oxidative 
pathway is the entrance into the TCA cycle; its components are shown in Figure 2.2. 
 
ENZYME  (Enzyme Commission number and name) 
     REACTION 
PDH  (EC 1.2.1.51  pyruvate dehydrogenase) 
     pyruvate + CoA + NAD+ = acetyl-CoA + CO2 + NADH 
PC  (EC 6.4.1.1  pyruvate carboxylase) 
     ATP + oxaloacetate = ADP + phosphoenolpyruvate + CO2 
CS  (EC 2.3.3.8  citrate synthase) 
     ADP + phosphate + acetyl-CoA + oxaloacetate = ATP + citrate + CoA 
ACT  (EC 4.2.1.3  aconitase) 
     (1) citrate = cis-aconitate + H2O; 
     (2) cis-aconitate + H2O = isocitrate 
IDH  (EC 1.1.1.42  isocitrate dehydrogenase) 
     (1) isocitrate + NAD+ = 2-oxoglutarate + CO2 + NADH + H+; 
     (2) oxalosuccinate + NAD+ = 2-oxoglutarate + CO2 + NADH + H+ 
KDH  (EC 1.2.7.3  α-ketoglutarate dehydrogenase complex) 
     2-oxoglutarate + CoA + NAD = succinyl-CoA + CO2 + NADH 
STK  (EC 6.2.1.5  succinate thiokinase) 
     ADP + phosphate + succinyl-CoA = ATP + succinate + CoA 
SDH  (EC 1.3.5.1  succinate dehydrogenase) 
     succinate + FAD = fumarate + FADH2 
FMS  (EC 4.2.1.2  fumarase) 
     fumarate + H2O = malate 
MDH  (EC 1.1.1.37  malate dehydrogenase) 
     malate + NAD+ = oxaloacetate + NADH + H+ 
MS  (malate shuttle) 
     transports malate across mitochondrial membrane 
Table 2.4.  Reactions of the Tricarboxylic Acid (TCA) Cycle.  Enzyme 
abbreviations correspond with those in Figure 2.2.  For each reaction, the full 
enzyme name and Enzyme Commission number is listed as well as the full 
reaction with all substrates, products and cofactors. 
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 Though many of these reactions are reversible, the favored direction of this cycle 
is typically clockwise.  In this direction, we can see in Table 2.4 that the reactions 
corresponding to IDH, KDH and MDH each release one molecule of NADH while the 
SDH reaction releases an FADH2.  These molecules enter phosphorylative oxidation to 
form 3 ATP for each molecule of NADH and 2 ATP for one molecule of FADH2.  
Pyruvate kinase activity is reduced when the glycolytic pathway is up-regulated.  
Assuming that pyruvate resulting from glycolytic activity enters the TCA cycle as acetyl-
CoA, then one glucose molecule entering glycolysis will result in two molecules of 
acetyl-CoA which allows for two turns of the TCA cycle.  We saw previously that there 
is a net gain of 2 ATP molecules during glycolysis from glucose to pyruvate.  Along with 
the 6 NADH and 2 FADH2 released during 2 turns of the TCA cycle and 2 NADH 
released during conversion of 2 molecules of pyruvate to 2 of acetyl-CoA by PDH, we 
now have: 2 ATP + 8 NADH + 2 FADH2 = 2 ATP + 24 ATP + 4 ATP = 30 ATP.  In the 
glycolytic pathway from glucose to pyruvate, the 2 molecules of NADH released during 
the GPD reaction yield 2 ATP molecules each through oxidative phosphorylation 
resulting in a total of 4 ATP molecules.  So in total, one glucose molecule completing the 
aerobic glycolysis pathway will release 34 ATP molecules, 32 more ATP molecules than 
through anaerobic glycolysis [10].  This magnifies the importance of maintaining blood 
glucose levels for those cells which lack mitochondria and thus lack the ability to produce 
ATP through oxidative phosphorylation.  The TCA cycle is a common ‘intersection’ of 





 When blood glucose levels drop below a certain threshold, the metabolic 
pathways in certain tissues are regulated so that alternate metabolic fuels such as amino 






























Figure 2.3.  The Complete Pathway of Gluconeogenesis.  Enzymes catalyzing 
specific reactions are denoted in boxes next to the arrow of each corresponding 
reaction.  Enzymes with dashed outlines are specific to glycolysis while those 
with outlined in solid are also found in gluconeogenesis.  Abbreviations are as 
follows:  G6Pase, glucose 6-phosphatase; PEPCK, phosphoenolpyruvate 
carboxykinase; MDH, malate dehydrogenase; MS, malate shuttle; TCA, 
tricarboxylic acid; ALT, alanine transaminase; PC, pyruvate carboxylase. 
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ENZYME  (Enzyme Commission number and name) 
     REACTION 
ALT  (EC 2.6.1.2  alanine transaminase) 
     alanine + α-ketoglutarate = pyruvate + glutamate 
PC  (EC 6.4.1.1  pyruvate carboxylase) 
     ATP + oxaloacetate = ADP + phosphoenolpyruvate + CO2 
MS  (malate shuttle) 
     transports malate across mitochondrial membrane 
MDH  (EC 1.1.1.37  malate dehydrogenase) 
     malate + NAD+ = oxaloacetate + NADH + H+ 
PEPCK  (EC 4.1.1.49  PEP carboxykinase) 
     ATP + oxaloacetate = ADP + phosphoenolpyruvate + CO2 
ENO  (EC 4.2.1.11  enolase) 
     phosphoenolpyruvate + H2O = 2-phospho-glycerate 
PGM  (EC 5.4.2.1  phosphoglycerate mutase) 
     2-phospho-glycerate = 3-phospho-glycerate 
PGK  (EC 2.7.2.3  phosphoglycerate kinase) 
     ATP + 3-phospho-glycerate = ADP + 1,3-bisphosphoglycerate 
GPD  (EC 1.2.1.12  glyceraldehyde 3-phosphate dehydrogenase) 
     1,3-bisphosphoglycerate + NADH + H+ = glyceraldehyde 3-phosphate + phosphate + NAD+ 
PTI  (EC 5.3.1.1  phosphotriose isomerase) 
     glyceraldehyde 3-phosphate = glycerone phosphate 
ALD  (EC 4.1.2.13  aldolase) 
     glycerone phosphate + glyceraldehyde 3-phosphate = fructose 1,6-bisphosphate 
FBP  (EC 3.1.3.11  fructose-1,6-bisphosphatase) 
     fructose 1,6-bisphosphate + H2O = fructose 6-phosphate + phosphate 
PHI  (EC 5.3.1.9  phosphohexose isomerase) 
     fructose 6-phosphate = glucose 6-phosphate 
G6Pase  (EC 3.1.3.9  glucose-6-phosphatase) 
     glucose 6-phosphate + H2O = glucose + phosphate 
Table 2.5.  Reactions of the Pathway of Gluconeogenesis.  Enzyme 
abbreviations correspond with those in Figure 2.3.  For each reaction, the full 
enzyme name and Enzyme Commission number is listed as well as the full 
reaction with all substrates, products and cofactors. 
 
glucose for those tissues that rely solely on glucose for energy production.  Along with 
switching over to using alternate fuels, some tissues also increase the rate at which 
gluconeogenesis occurs.  Gluconeogenesis is the metabolic pathway by which amino 
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acids are used to form glucose and occurs in select tissues, mainly liver and kidney.  The 
complete pathway of gluconeogenesis can be seen in Figure 2.3. 
Regulation of the reactions in these pathways causes a switching to occur so that 
one is emphasized more than the other depending on the state of glucose intake of the 
system, futile cycling occurs since each pathway still has some amount of flux no matter 
the state of glucose intake.  Some futile cycling occurs but it has been observed that the 
net flux of these pathways is what switches in response to an increase or decrease of 
blood glucose levels.  Though observation of futile cycling of these two pathways has 
been documented, there is still much unknown about costs and benefits to the system as a 
result of this phenomenon. 
 
2.3.3 Glycogenesis 
As glycogen is the stored form of glucose, we will consider glucose the starting 
substrate when considering the pathway of glycogenesis, leading to the formation of 
glycogen.  The first step in this pathway is the same as that of glycolysis, hexokinase or 
glucokinase converting glucose to glucose 6-phosphate.  Glucose 6-phosphate is an 
interesting metabolite to study as multiple pathways connect through this compound.  For 
simplification purposes Only four of these pathways are considered: glycolysis, 
gluconeogenesis, glycogenesis, and glycogenolysis.  One neglected pathway worth 
mentioning is the pentose phosphate pathway which is an alternate pathway for the 
conversion of glucose 6-phosphate to phosphoenolpyruvate, a participant in glycolysis 














Figure 2.4.  The Complete Pathway of Glycogenesis.  Enzymes catalyzing 
specific reactions are denoted in boxes next to the arrow of each corresponding 
reaction.  Abbreviations are as follows:  HK, hexokinase; GK, glucokinase; 
PGM, phosphoglucomutase; UDPgase, uridine diphosphoglucose 
pyrophosphorylase; GS, glycogen synthase. 
 
ENZYME  (Enzyme Commission number and name) 
     REACTION 
HK, GK  (EC 2.7.1.1  hexokinase, EC 2.7.1.2  glucokinase) 
     ATP + glucose = ADP + glucose 6-phosphate 
PGM  (EC 5.4.2.2  phosphoglucomutase) 
     glucose 6-phosphate = glucose 1-phosphate 
UDPgase  (EC 2.7.7.9  UDP glucose pyrophosphorylase) 
     UTP + glucose 1-phosphate = diphosphate + UDP-glucose 
GS  (EC 2.4.1.11 glycogen synthase) 
     UDP-glucose + (1,4-glucosyl)n = UDP + (1,4-glucosyl)(n+1) 
Table 2.6.  Reactions of the Complete Pathway of Glycogenesis.  Enzyme 
abbreviations correspond with those in Figure 2.4.  For each reaction, the full 
enzyme name and Enzyme Commission number is listed as well as the full 
reaction with all substrates, products and cofactors. 
 
phosphate to glycerol.  Although these pathways are not considered here it is important to 
keep in mind the complexity of this system in its true environment.  The rate at which 
glycogenesis occurs increases when glucose levels are high.  In order for glycogen to 
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form, an initial or starter compound called glycogenin is needed.  The glucose partitions 
of intermediary compounds in this pathway bind to glycogenin and then to each other 
resulting in a branched chain-like structure of glucose molecules.  A diagram of 
glycogenolysis is shown in Figure 2.3. 
 
2.3.4 Glycogenolysis 
Using glycogen as a source of glucose is the fastest pathway to regulate when 
blood glucose levels drop and a supply of glucose is needed immediately.  Just as 
gluconeogenesis did not use the same pathway as glycolysis in reverse, glycogenolysis 
does not simply reverse the reactions in glycogenesis.  One less step is needed for 
glycogenolysis as uridine diphosphoglucose is not a component of this pathway.  Figure 













Figure 2.5.  The Complete Pathway of Glycogenolysis.  Enzymes catalyzing 
specific reactions are denoted in boxes next to the arrow of each corresponding 
reaction.  Abbreviations are as follows:  G6Pase, glucose 6-phosphatase; PGM, 
phosphoglucomutase; GP, glycogen phosphorylase. 
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 In this pathway, not only are different enzymes required but glycogen is directly 
converted to glucose-1-phosphate and the step involving uridine diphosphoglucose is not 
needed.  The only enzyme that this pathway has in common with glycogenesis is 
phosphoglucomutase.  The activation of glycogen synthase and glycogen phosphorylase 
is tightly regulated by complex circuit of enzymes.  This regulatory circuit will be 
described in more detail in Chapter 3. 
 
ENZYME  (Enzyme Commission number and name) 
     REACTION 
GP  (EC 2.4.1.1  glycogen phosphorylase) 
     ATP + glucose = ADP + glucose 6-phosphate 
PGM  (EC 5.4.2.2  phosphoglucomutase) 
     glucose 1-phosphate = glucose 6-phosphate 
G6Pase  (EC 3.1.3.9  glucose-6-phosphatase) 
     glucose 6-phosphate + H2O = glucose + phosphate 
Table 2.7.  Reactions of the Pathway of Glycogenolysis.  Enzyme abbreviations 
correspond with those in Figure 2.5.  For each reaction, the full enzyme name 
and Enzyme Commission number is listed as well as the full reaction with all 




Lipogenesis is a very complex process involving numerous conversion steps.  The 





ENZYME  (Enzyme Commission number and name) 
     REACTION 
CL  (EC 2.3.3.8  ATP citrate lyase) 
     ATP + citrate + CoA = ADP + phosphate + acetyl-CoA + oxaloacetate 
AC  (EC 6.4.1.2  acetyl-CoA carboxylase) 
     ATP + acetyl-CoA + HCO3- = ADP + phosphate + malonyl-CoA 
ACT  (EC 2.3.1.38  acetyl transacylase) 
     acetyl-CoA + [acyl-carrier protein] = CoA + acetyl-[acyl-carrier protein] 
MT  (EC 2.3.1.39  malonyl transacylase) 
     malonyl-CoA + [acyl-carrier protein] = CoA + malonyl-[acyl-carrier protein] 
KAS  (EC 2.3.1.41  3-ketoacyl synthase) 
     acyl-[acyl-carrier protein] + malonyl-[acyl-carrier protein] =  
     3-oxoacyl-[acyl-carrier protein] + CO2 + [acyl-carrier protein] 
KAR  (EC 1.1.1.100  3-ketoacyl reductase) 
     3-oxoacyl-[acyl-carrier protein] + NADPH + H+ =  
     3-hydroxyacyl-[acyl-carrier protein] + NADP+ 
HT  (EC 4.2.1.58  hydratase) 
     3-hydroxybutanoyl-[acyl-carrier protein] = but-2-enoyl-[acyl-carrier protein] + H2O 
ER  (EC 1.3.1.10  enoyl reductase) 
     CoA + 3-oxoacyl-CoA = acyl-CoA + acetyl-CoA 
after cycling through last 4 reactions: 
TE  (EC 3.1.2.14  thioesterase) 
     oleoyl-[acyl-carrier protein] + H2O = [acyl-carrier protein] + oleate 
Table 2.8.  Reactions of the Pathway of Lipogenesis.  For each reaction, the full 
enzyme name and Enzyme Commission number is listed as well as the full 




It is common knowledge that exercise is effective in reducing the amount of fat in 
the body.  The properties of one’s diet also assists in reducing fat.  Fat from the diet 




















Figure 2.6.  The Complete Pathway of Lipolysis.  Enzymes catalyzing specific 
reactions are denoted in boxes next to the arrow of each corresponding reaction.  
Abbreviations are as follows:  ACS, acyl-coenzyme A synthetase; CT, carnitine 
transporter; ADH, acyl- coenzyme A dehydrogenase; ECH, ∆2-trans-enoyl-
coenzyme A hydratase; HDH, 3-hydraoxyacyl-coenzyme A dehydrogenase; TL, 
thiolase. 
When glucose levels drop, the rate at which fat stores break down is increased as they  
will serve to pick up some of the slack for energy production due to a lack of glucose.  
Fats are unable to enter the gluconeogenic pathway to form glucose.  This is discussed 
later with the roles of various tissues within metabolism.  Fats cannot be made into 
glucose.  However, fats are able to, through lipolysis, be metabolized to acetyl-CoA 
which is oxidized through the TCA cycle, providing necessary substrate for the 
respiratory chain, producing energy.  So fats do provide energy for the tissue in which 
they reside but are unable to provide energy to other tissues.  Fats are transported to other 
tissues and provide energy to use amino acids as a source of glucose in those tissues.  As 
glucose is plentiful during feeding, lipolysis occurs as a slow rate as fats are not needed.  
As glucose levels drop, we see a rise in the rate of lipolytic reactions.  Figure 2.7 and 
table 2.9 detail the steps of lipolysis. 
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ENZYME  (Enzyme Commission number and name) 
     REACTION 
ACS  (EC 6.2.1.3  acyl-CoA synthetase) 
     ATP + a long-chain carboxylic acid + CoA = AMP + diphosphate + an acyl-CoA 
CT  (Carnitine Transporter) 
     transports acyl-CoA across the mitochondrial membrane 
ADH  (EC 1.3.99.3  acyl-CoA dehydrogenase) 
     acyl-CoA + acceptor = 2,3-dehydroacyl-CoA + reduced acceptor 
ECH  (EC 4.2.1.17  ∆2-enoyl-CoA hydratase) 
     trans-2(or 3)-enoyl-CoA + H2O = 3-hydroxyacyl-CoA 
HDH  (EC 1.1.1.35  3-hydroxyacyl-CoA  dehydrogenase) 
     3-hydroxyacyl-CoA + NAD+ = 3-oxoacyl-CoA + NADH + H+ 
TL  (EC 2.3.1.16  3-ketoacyl-CoA thiolase) 
     CoA + 3-oxoacyl-CoA = acyl-CoA + acetyl-CoA 
Table 2.9.  Reactions of the Pathway of Lipolysis.  Enzyme abbreviations 
correspond with those in Figure 2.7.  For each reaction, the full enzyme name 
and Enzyme Commission number is listed as well as the full reaction with all 
substrates, products and cofactors. 
 
2.3.7 Ketogenesis 
Just as fats are able to provide an alternate fuel source in a time of ‘glucose 
drought’, ketone bodies are also able to play this role.  As Figure 2.8 shows, we see that 
ketogenesis consists of a few steps and is tightly connected to the end result of lipolysis.  
Whereas fats only provide energy to the tissue in which the breakdown of these fats 
occur, ketone bodies can be thought of as an extension of fat breakdown, an extension in 
that ketone bodies are transported to other tissues where they are oxidized and enter the 
TCA cycle making substrate for the respiratory chain and thus providing energy for those 
























Figure 2.7.  The Complete Pathway of Ketogenesis.  Enzymes catalyzing 
specific reactions are denoted in boxes next to the arrow of each corresponding 
reaction.  Abbreviations are as follows:  ACS, acyl-coenzyme A synthetase; CT, 
carnitine transporter; ADH, acyl- coenzyme A dehydrogenase; ECH, ∆2-trans-
enoyl-coenzyme A hydratase; HDH, 3-hydraoxyacyl-coenzyme A 
dehydrogenase; TL, thiolase; FAO, fatty acid oxidase. 
 
ENZYME  (Enzyme Commission number and name) 
     REACTION 
HMGS  (EC 2.3.3.10  HMG-CoA synthase) 
     acetyl-CoA + H2O + acetoacetyl-CoA = 3-hydroxy-3-methylglutaryl-CoA + CoA 
HMGL  (EC 4.1.3.4  hydroxymethylglutaryl-CoA lyase) 
     3-hydroxy-3-methylglutaryl-CoA = acetyl-CoA + acetoacetate 
HBD  (EC 1.1.1.30  3-hydroxybutyrate dehydrogenase) 
     acetoacetate + NADH + H+ = 3-hydroxybutanoate + NAD+ 
Table 2.10.  Reactions of the Pathway of Ketogenesis.  Enzyme abbreviations 
correspond with those in Figure 2.8.  For each reaction, the full enzyme name 
and Enzyme Commission number is listed as well as the full reaction with all 
substrates, products and cofactors. 
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2.4 Regulation of the Metabolic System 
 
The types of regulation currently in the model are allosteric regulation, or the 
physical modification of an enzyme which affects its level of activity, and hormonal 
regulation, in which signal transduction resulting from the binding of hormones to cell 
surface receptors affects the rate of a biochemical reaction.  Transcriptional regulation 
affects the level of enzyme present thus affecting the rate of activity of the corresponding 
enzyme.  This regulation is not currently present in this model but is discussed more in 
the section of future direction for this model. 
 
2.4.1 Allosteric Regulation 
 Enzymes initiate allosteric regulation by binding to a protein and increasing or 
decreasing the activity of a certain reaction involving that protein.  The modeling of this 
type of regulation is discussed in Chapter 4. 
 
2.4.2 Hormonal Regulation 
Insulin and glucagon are two hormones secreted from the pancreas that are vital 
for functional regulation of the metabolic system.  Many published mathematical models 
describe the relationship between glucose, insulin and glucagon [5-8].  While 
demonstrating the dependency of glucose and these two hormones, these models provide 
a limited inclusion of the mechanisms but which this dependency exists.  My proposed 
model includes many mechanisms for which hormonal regulation stabilizes blood 
glucose levels such as insulin-dependent glucose transporters and hormonal-dependent 
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regulation of glycogen.  To compensate for the lack of a pancreatic component in my 
model, glucose directly regulates insulin and glucagon within the blood.  Glucose 
increases the rate of insulin secretion while increasing the rate of glucagon degradation 
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Insulin and glucagon were each given a level of basal secretion as well as a rate of 
decay.  The blood insulin concentration within the model, [B_Ins], stays between .7 * 10-6 
mM and 1.3 * 10-6 mM (refs) while the blood glucagon concentration, [B_Glucgn], stays 
between 3 * 10-8 mM and 5 * 10-8 mM [16, 17].  By making parameters kmIns = 8 and 
kmGlucgn = 8, hormone concentrations approach their half max average value ([B_Ins] = 1 
* 10-6 mM and [B_Glucgn] = 5 * 10-8 mM) as blood glucose levels approach 8 mM.  Hill 
coefficients, ni and ng, were added to increase switch-like behavior. 
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Figure 2.8.  Insulin and Glucagon in Relation to Glucose.  Blood insulin levels 
as a function of glucose is shown in A while blood glucose levels as a function 
of glucose is shown in B. 
 
Rates affected by the presence of insulin or glucagon are multiplied by factors.  
The values of these factors for insulin regulation in the model range between 0 and 1 and 
most are set to reach a value of 1
2
 when [B_Ins] reaches 1 * 10-6 mM (model parameter 
kDins) while the remaining multiplicative factors reach a value of 12  when [B_Ins] reaches 
0.75 * 10-6 mM (model parameter kDins2).  Values of multiplicative factors for glucagon 
regulation in the model also range between 0 and 1 and all are set to reach a value of 1
2
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The above rate (for conversion of glucose 6-phosphate to phosphoenolpyruvate) 
gives examples of both positive regulation by insulin and negative regulation by 
glucagon.  This rate was designed so that in the absence of hormones ([B_Ins] = 0 and 
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Figure 2.9.  Regulatory Multiplicative Factors.  The value of a negative 
regulatory multiplicative factor dependent on blood insulin levels is shown in A. 
Figure B shows the values of a multiplicative factor which determine negative 




cAMP is a secondary signal for hormonal regulation.  Through signal 
transduction, insulin increases the rate at which cAMP is degraded [10] thus having a 
negative affect on cAMP concentration levels.  Conversely, through signaling glucagon 
increases the amount of cAMP present.  For the model, concentration levels of cAMP 
were designed with similar features as insulin and glucagon growth and decay such as 
staying within a specified range and producing switch-like behavior for regulation 
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purposes as glucose levels reach 8 mM.  cAMP is kept with the range of 2.4 * 10-6 mM 
and 4.3 * 10-6 mM [10, 16, 17] and the multiplicative factor of reactions regulated by 
cAMP equal 1
2
 when [cAMP] = 1 * 10-5.5.  
 
 
















Figure 2.10.  cAMP in Relation to Glucose.  Liver cAMP concentration level as 












Glycogen Regulatory Circuit 
 
3.1 From Glucose to Glycogen and Back 
As the main purpose of the regulation of glycogenesis and glycogenolysis is to 
maintain blood glucose levels, the pathway in which glucose is converted into glycogen 
and back should be outlined before detailing the structure of the glycogen regulatory 
circuit.  While glycogen stores are found mainly in liver and muscle, the purpose and 
regulation of these stores differs.  This thesis will focus on the regulation of hepatic 
glycogen as this store of glycogen is used to maintain blood glucose levels while muscle 
glycogen stores are used to provide immediate energy for the muscles in which the 
glycogen is stored.  To simplify this system, the processes involved in creating and using 
glycogen stores will be considered for a single, well-mixed cell. 
Glucose is passively transported across the hepatic cell membrane through the 
glucose transporter GLUT2 [9, 10].  Either hexokinase or glucokinase converts glucose to 
glucose 6-phosphate by adding a phosphate group to the sixth carbon molecule of 
glucose.  This phosphate group is switched with another phosphate group in a 
bisphosphate molecule which is then attached to the first carbon molecule by 
phosphoglucomutase (EC 5.4.2.2) to form glucose 1-phosphate.  Uridine 
diphosphoglucose pyrophosphorylase (EC 2.7.7.9) converts glucose 1-phosphate to 
uridine diphosphoglucose, UDP-glucose.  Glycogen synthase (EC 2.4.1.11) then transfers 
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the glucose partition of UDP-glucose onto an existing structure of glycogen.  The first 
enzyme in the pathway of glycogenolysis is glycogen phosphorylase (EC 2.4.1.1) which 
combines a glucose residue from glycogen with a phosphate group, forming glucose 1-
phosphate.  Phosphoglucomutase, the enzyme which converted glucose 6-phosphate to 
glucose 1-phosphate catalyzes a reversible reaction so that it also converts glucose 1-
phosphate back to glucose 6-phosphate.  Glucose 6-phosphatase (EC 3.1.3.9) then 
converts glucose 6-phosphate back to glucose which is transported from the liver through 
GLUT2.  Figures portraying the pathways of glycogenesis and glycogenolysis pathways 
were shown in Figure 2.4 and Figure 2.5. 
In order to study the regulatory circuit behind the activation of glycogen synthase 
and glycogen phosphorylase, this system has been slightly simplified by deleting three 
steps from these pathways.  Glucose 1-phosphate and UDP-glucose have been removed 
and the levels of blood glucose and liver glucose are assumed to be indistinguishable.  
These changes are reasonable as glycogen synthase and phosphorylase are the rate 
limiting enzymes in the pathways between glucose 6-phosphate and glycogen.  These 
changes leave three metabolites:  glucose, glucose 6-phosphate and glycogen. 
This is an open system since glucose enters through feeding and exits as the liver 
adapts to providing glucose during low blood glucose levels.  Flux in and out of the 
glucose 6-phosphate occurs through the glycolytic and gluconeogenic pathways.  
Glycolysis is the pathway by which the cell, through a number of processes, converts 
glucose to form ATP, providing energy for cellular functions.  Gluconeogenesis is the 
pathway in which amino acids are eventually used to make glucose and is fueled by the 
breakdown of free fatty acids. 
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It is known that glucose increases the rate at which insulin is secreted from the 
beta-cells in the pancreas and also acts as an inhibitor for the secretion of glucagons from 
the pancreatic alpha-cells [14, 15].  Insulin and glucagon both bind to respective 
receptors and initiate signal transduction to regulate metabolic activity within 
hepatocytes.  Though the regulatory hormones insulin and glucagon originate from the 
pancreas, for simplification purposes, it will be assumed that these are solely located in 
the blood.  A secondary signal which becomes a main regulator of glycogenic activity is 
cAMP.  The production of this compound is increased by the signaling from glucagon 
while insulin signals an increase in the decay of cAMP [10]. 
 
3.2 Circuit Architecture 
 Glycogen synthase and glycogen phosphorylase both undergo covalent 
modification which determines whether each enzyme is in an active or inactive state.  
cAMP initiates phosphorylation of a number of enzymes structured in a cascade which 
eventually results in the phosphorylation, or the addition of a phosphate group, to 
glycogen synthase and glycogen phosphorylase.  Unlike glycogen phosphorylase which 
is activated while in the phosphorylated state, glycogen synthase is activated while in the 
unphosphorylated state.  By cAMP signaling the phosphorylation of these enzymes 
simultaneously, it results in a shifting of the net glycogenic flux by regulating two 
pathways, glycogenesis and glycogenolysis, through one cascade structure.  This 
structure begins with cAMP binding to cAMP-dependent protein kinase, or protein kinase 
A, releasing the catalytic subunit of protein kinase A.  This subunit phosphorylates 
phosphorylase kinase which activates this enzyme.  When activated, this enzyme 
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catalyzes the phosphorylation of both glycogen synthase and glycogen phosphorylase.  
The catalytic subunit of protein kinase A also initiates phosphorylation of glycogen 
synthase but not of glycogen phosphorylase.  Protein phosphatase 1 dephosphorylates 
glycogen synthase, glycogen phosphorylase and phosphorylase kinase.  A diagram for 






















Figure 3.1.  Glycogen Regulatory Circuit.  The conversion between glucose, 
glucose-6-phosphate and glycogen is shown along with the cascade of enzymes 
that regulate this conversion.  The hormones insulin and glucagon, regulated by 
glucose, are key regulators of this enzyme cascade.  cAMP, cyclic adenosine 
monophosphate; R2C2, cAMP dependent protein kinase; C, R2C2 catalytic 
subunit; PKb, inactive phosphorylase kinase; PKa, active phosphorylase kinase; 
GPb, inactive glycogen phosphorylase; GPa, active glycogen phosphorylase; 
GSb, inactive glycogen phosphorylase; GSa, active glycogen phosphorylase; P, 







4.1 Enzyme Kinetics 
 
Enzymes are proteins that act as catalysts for biochemical reactions.  The rate of 
reaction is dependent on the amount of substrate present and the rate constant specific to 
that reaction.  The value of a rate constant can sometimes be determined experimentally 
and often depends on multiple factors such as the pH level of the environment.  The 
current model uses a combination of mass action kinetics and Michaelis-Menten kinetics 
[18] to mathematically describe the rates of the chemical reactions involved.  This section 
outlines both types of kinetics.   
 
4.1.1  Mass Action Kinetics 
The theory of mass action kinetics is based on the concept that the rate of a 
chemical reaction is dependent on the probabilities of the molecules necessary for that 
reaction to occur to be present together in the same proximity.  These probabilities are 
assumed to be independent and so the rate will be the product of the relevant 
concentrations for the reaction.  As an example, for the basic conversion of molecule A to 
molecule B, A    B, the rate can be approximated by a rate constant times the amount of 
 38 
[A] present, or v1  =   k1 [A], where v1 is the rate of the reaction and k1 is a first order rate 
constant.  Below are a few more examples of this theory: 
 
1) A + A    B,  v1  =   k1 [A] [A]  =   k1 [A]2,  k1 is second order 
2) A + B    C,  v1  =   k1 [A] [B],   k1 is second order 
 
 In building an ODE model, these mathematical descriptions are then used to 
describe the rate of change of a concentration.  For example, in the second reaction 
above, [A] and [B] change in a negative manner, each losing one unit of mass and while 
one unit of mass is being added to [C].  A system of ODEs to describe the change in mass 
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4.1.2  Michaelis-Menten Kinetics 
Mass action kinetics assumes that the rate is directly proportional to the 
probabilities that relevant concentrations will be present.  In the late nineteenth century, 
Brown noted that enzyme catalyzed reactions did not follow second-order kinetics.  A 
few years earlier, the formation of an enzyme-substrate complex during a reaction was 
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discovered by O’Sullivan and Tompson.  While Brown did the initial work on describing 
the kinetics of this enzyme-substrate complex, Henri went on to describe these kinetics in 
a more mathematical sense and in 1913, Michaelis and Menten introduced their well-
known equation [18].  Substrate S and enzyme E bind to form the substrate-enzyme 
complex SE before the enzyme dissociates and product P is released.  The formation of 
SE is reversible while the dissociation of E and P is irreversible.   







Enzyme E is found either in free form or in the substrate-enzyme complex, SE.  The total 
amount of enzyme E is: 
[ ]    [ ] + [ ]TE SE E=  
It is assumed that [SE] reaches steady state. 
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Dividing the numerator and denominator by k1 gives 
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The rate limiting step for this process is the dissociation of the enzyme and release of 
product P.  The rate of this reaction is given by: 
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=  is known as the Michaelis-Menten constant and max 2  [ ]TV k E=  is the 
maximum reaction rate using the total amount of enzyme.  This equation provides an 
approximation for the initial rates of biochemical reactions.  As [S] goes to zero, the 
velocity also goes to zero.  As [S] grows, v approaches an asymptotic value of v  =  k2 
[E]T., or Vmax.  If Keq  =  [S], then v2  =  12  Vmax.   
 
 
4.2 Literature Review 
While many mathematical models exist for various structures and pathways 
within the metabolic system, these models have been studied in isolation from the rest of 
this system.  As technology has allowed us to collect vast data on specific reactions, we 
have been able to look more closely at these pathways but need to be careful to not 
neglect the big picture that enfolds from metabolism.  While a whole physiological model 
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of metabolism has yet to be offered, two papers propose models for the glycogen 
regulatory circuit, one determining steady state behavior and the other time dependent 
behavior. 
Steady state properties were studied comparing results of this local system in the 
liver and in the muscle [19].  Though this circuit is very similar in both tissues, there are 
important differences that allow for separate function of the glycogen stores.  This paper 
does not detail the differential equations used to model this system but does offer the 
resulting equations used for steady state analysis.  The behavior of glycogen synthase and 
phosphorylase activation was found to be extremely switch-like in response to changing 
cAMP levels.  Glycogen synthase was more sensitive than glycogen phosphorylase in the 
liver but the opposite was true for the muscle.  Futile cycling was observed during a 
starved state but was not present while the system was in a fed state.  
A 2-dimensional system of ordinary differential equations was introduced [20] to 
explore the dynamics of metabolic regulation of glycogen synthase and glycogen 
phosphorylase in response to particular levels of glucose concentration.  During the fed 
state, a delayed effect on activation of glycogen synthase was found due to inhibition of 
synthase by activated glycogen phosphorylase.  This inhibition by activated 
phosphorylase becomes insignificant when activated phosphorylase is below a certain 
threshold or where there is not a sufficient amount of glycogen as is the case with fasted 
animals (futile cycling is not mentioned in this paper).  This model exhibits the need for 
an increase in glucose-6-phosphate and a decrease in glycogen synthase to activate 
‘glycogen synthase to significant levels’.  It is the ratio of the synthase phosphatase to 
synthase kinase that determines the activation of glycogen synthase and this ratio is 
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controlled by levels of glucose-6-phosphate and activation glycogen phosphorylase.  
Although not observed thus far, the possibility of these enzymes exhibiting ‘zero-order 
ultrasensitivity’, operating in the domain where they are near saturation with respect to 
their substrate, was suggested. 
 
4.3 Broad Contextual Model 
Our first main goal for designing a contextual or whole-physiological model for 
the metabolic system was to capture the dynamical shift in concentration levels for the 




























Figure 4.1.  Effects of Fasting.  Blood glucose, liver glycogen and plasma 
insulin levels drop as plasma glucagon, free fatty acids and blood ketone bodies 
levels increase in response to a fasted state. 
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relative change in levels of blood glucose, liver glycogen, plasma free fatty acids, blood 
ketone bodies, plasma insulin and plasma glucagon are shown in Figure 4.1 (recreated 
from [10]). 
As the system enters into fasting, blood glucose levels are stabilized for a brief 
period before decreasing to the loss of glucose influx from digestion.  Liver glycogen is 
depleted as it is being used to form glucose to stabilize the blood glucose levels.  As the 
amount of hepatic glycogen decreases, plasma free fatty acid levels rise reflecting the 
breakdown of fats from fat tissue and transport of these fats in the bloodstream to the 
liver and other tissues to be an alternate metabolic fuel.  There is also a rise in the level of 
ketone bodies in the blood as they are a byproduct of lipolysis.  Ketone bodies are used 
by select tissues as a metabolic fuel but a high concentration of ketone bodies, resulting 
in ketoacidosis, is harmful for the body.  Ketone bodies when present in large quantities 
can lower the pH level of the body, interrupting the normal function of many biochemical 
processes.  The heart uses a large amount of free fatty acids and ketone bodies for fuel.  
The brain also relies on ketone bodies as extra fuel when glucose levels are low.  Insulin 
and glucagon levels vary in response to glucose levels with insulin secretion from the 
pancreas being up-regulated by glucose and glucagon secretion from the pancreas being 
down-regulated by glucose.  As mentioned earlier, pervious mathematical models have 
explored the effects of glucose on insulin and glucagon and the feedback of these 
hormones regulating blood glucose levels but have provided only a vague idea of how 
insulin and glucagon execute this regulation.  The dynamical changes in concentration 
levels of the select metabolites in Figure 4.1 are a result of the levels of insulin and 
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The liver will contain the most detailed pathways for our model as the liver is the 
control center for metabolism partially due to the fact that it is able to process alternate 
metabolic fuels from within the liver as well as other tissues and form glucose and secrete 
it into the blood.  The liver also is the place of ketogenesis thus providing alternate 
energy substrate as well as glucose.  Table 4.1 lists the simplified metabolic pathways 
used in the model for the liver and Figure 4.2 organizes these pathways in a diagram. 
 
glycolysis gluc  g6p  pep  pyr 
gluconeogenesis alan  pyr  oa_m  malate  oa_c  pep  g6p  gluc 
TCA cycle oa_m  cit  aK  malate  oa_m 
glycogenesis gluc  g6p  glycgn 
glycogenolysis glycgn  g6p  gluc 
lipogenesis cit  acet_c  palm 
lipolysis palm  palmCoA  acet_m 
ketogenesis acet_m  ket 
Table 4.1.  Simplified Metabolic Pathways for the Liver.  Gluc, glucose; g6p, 
glucose-6-phosphate; pep, phosphoenolpyruvate; alan, alanine; oa_m, 
mitochondrial oxaloacetate; oa_c, cytosolic oxaloacetate; cit, citrate; aK, alpha-
ketoglutarate; glycgn, glycogen; acet_c, cytosolic acetyl Coenzyme A; palm, 





























































Figure 4.2.  Reactions Included in Liver Component of the Model.  The 
corresponding rate of each reaction is described in the text 
A set of full equations is given in Appendix A.  We will step through the model 
one reaction at a time to see how the dynamics of this system were captured 
mathematically.  The first step of glycolysis is the conversion of glucose to glucose 6-
phosphate, denoted by vL1.  While this reaction is catalyzed by both hexokinase and 
glucokinase, this reaction is simplified by assuming the presence of one enzyme.  This 
reaction is up-regulated through insulin signaling.  This reaction takes on a Michaelis-
Menten form and is multiplied by a factor that allows for a flux independent of insulin 
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 The next step of simplified glycolysis is from glucose 6-phosphate to 
phosphoenolpyruvate.  While vL3 combines a number of reactions within glycolysis, the 
enzyme of main importance is phosphofructokinase (see Figure 2.1) since this is the 
enzyme in glycolysis in which the direction of flow differs from gluconeogenesis.  The 
form of this reaction is similar to the previous one except that the rate of this reaction 
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 Phosphoenolpyruvate now gets converted to pyruvate by pyruvate kinase.  The 
regulation of this reaction by hormones is similar to the previous step.  An added factor is 
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 Pyruvate kinase catalyzes an irreversible reaction so pyruvate is unable to be 
converted directly back to phosphoenolpyruvate.  The options for pyruvate in the model 
are to proceed through anaerobic glycolysis and be converted to lactate, be oxidized to 
oxaloacetate or to acetyl-CoA.  Though the model does not take into consideration the 
spatial effects on the dynamics, it is worth keeping in mind that these options for 
pyruvate take place in the mitochondria whereas glycolysis takes place in the cytosol.  
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The conversion of pyruvate to lactate is a reversible reaction catalyzed by lactate 


































Pyruvate enters aerobic glycolysis by being converted to acetyl-CoA via pyruvate 






   











Pyruvate also plays a role in gluconeogenesis by being converted to oxaloacetate 
via pyruvate carboxylase. Within our model, gluconeogenesis begins with the 
transamination of amino acids so we will look at this step next.  Instead of looking at all 
amino acids, we will just look at alanine and glutamine as these play a major role in the 
breakdown of proteins for gluconeogenesis and the metabolism of nitrogen, two areas of 
interest for this project.  The reaction catalyzed by alanine aminotransferase is reversible 
and results in the transfer of an amino group from alanine to α-ketoglutarate to form 
glutamate with pyruvate being the result of the remains of alanine.  Glutamate was at first 
not included within this model, however was later included to allow for the possibility of 
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the urea cycle which concerns nitrogen metabolism.  Insulin signaling reduces the affects 
of this enzyme.  Our model assumes Michaelis-Menten dynamics with respect to each 
substrate in these reactions. 
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Pyruvate carboxylase activity, vL6, which converts pyruvate to oxaloacetate in the 
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From here, we have now entered the TCA cycle.  To follow the shortest path of 
gluconeogenesis, we will only look at the step of the cycle involving conversion of 
mitochondrial oxaloacetate to malate as malate is shuttled out from the mitochondrial to 
leave the region in which gluconeogenesis has reactions in common with the TCA cycle.  
We will come back to look at the reactions in the TCA cycle.  Malate dehydrogenase 
converts oxaloacetate to malate in both the cytosol and the mitochondria and this reaction 
is reversible.  We will consider the reverse reaction for the mitochondrial portion when 
discussing the other TCA cycle reactions.  The reaction from oxaloacetate to malate in 
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the mitochondria is positively regulated by glucagon signaling and has linear dynamics 
with respect to oxaloacetate. 
 
5
11 11 5 5
[ _ ]
   [ _ ] 1  
  [ _ ]
ep
L L ep ep
Dglucgn
B glucgn
v k oa m
k B glucgn
 
= +  + 
 
 
Malate is transported through the mitochondrial membrane and converted back to 
oxaloacetate in the cytosol.  Oxaloacetate is not able to be transported across the 
mitochondrial membrane so it must be converted to malate first. 
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Phosphoenolpyruvate carboxylase converts oxaloacetate to phosphoenolpyruvate.  
Again, our model assumes linear dynamics with respect to oxaloacetate and is double 
regulating by insulin and glucagon, through a negative and a positive manner 
respectively.         
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We saw that although the pathway from glucose 6-phosphate to phosphoenolpyruvate 
had multiple steps, only one step was irreversible and so two different enzymes are 
required to complete this pathway.  The reaction by one enzyme, phosphofructokinase 
(vL3), is increased during glycolysis and the reaction by the other enzyme, fructose-1,6-
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bisphosphatase (vL-3), is increased during gluconeogenesis.  We assume Michaelis-
Menten kinetics in this reaction and account for positive regulation by glucagon signaling 
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The last step of gluconeogenesis is the conversion of glucose 6-phosphate into 
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As for the reactions affecting the storage of glycogen, this is currently the only 
area in the model in which the amounts of enzymes present were explicitly modeled.  The 
steps involving conversion of glucose to glucose 6-phosphate (vL1) and back (vL-1) were 
listed already.  Our simplified process of glycogenesis involves glucose 6-phosphate 
being directly stored as glycogen and the main enzyme of this process is glycogen 
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Going back to the TCA cycle, we have already discussed the entrance of pyruvate 
to the TCA cycle through either acetyl-CoA during glycolysis or oxaloacetate during 
gluconeogenesis.  Citrate synthase combines oxaloacetate and acetyl-CoA to form citrate.  
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The model combines multiple steps to connect the pathway from citrate to α-
ketoglutarate.  Though these reactions are reversible, they are assumed irreversible in the 
model for simplification of pathways.  Linear dynamics are assumed. 
 
9 9   [ ]L Lv k citrate=  
 
Again multiple steps are combined into one when modeling the conversion of α-
ketoglutarate to malate. 
 
10 10   [ ] L Lv k aK=  
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We now list the reversible reaction of malate dehydrogenase to convert malate to 
oxaloacetate completing the cycle. 
 
- 11 - 11   [ ]L Lv k malate=  
 
We now leave the TCA cycle to look at the pathway of lipogenesis.  Just as 
oxaloacetate and acetyl-CoA were combined to form citrate, citrate is transported to the 
cytosol where citrate lyase breaks down citrate to form acetyl-CoA and oxaloacetate.  
Due to the role of oxaloacetate and acetyl-CoA various pathways of different location in 
the cell, a separate concentration of each is considered in the model for the mitochondrial 
concentration and the cytosolic concentration.  The activity of citrate lyase is increased 
due to insulin signaling but decreased due to glucagon signaling.  
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Acetyl-CoA and malonyl-CoA together enter a complicated process to form 
palmitate, a free fatty acid (see Figure 2.6).  This process starts with one molecule of 
acetyl-CoA and one of malonyl-CoA and then forms a fatty acid complex which cycles 
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through a four enzyme process.  The complex goes through this cycle seven times and 
each time picks up another molecule of malonyl-CoA producing a stoichiometry of 1:7:1 
for acetyl-CoA to malonyl-CoA to palmitate. 
 
7
16 16   [ _ ] [ ]L Lv k acet c malonyl=  
 
When blood glucose levels drop, the transport of free fatty acids from fat to blood 
and then from blood to the liver increases.  These free fatty acids, restricted to palmitate 
in our model, break down in tissues to palmitate-CoA, also known as acyl-CoA.  The 





   











 Acyl-CoA is transported across the mitochondrial membrane where it is converted 
to acetyl-CoA.  This step is also down-regulated by malonyl-CoA.  In order to 
differentiate between certain pathways, it was necessary in our model to consider which 
processes took place in the mitochondria and which in the cytosol.  However, our model 
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 The role of acetyl-CoA in the TCA cycle by forming citrate along with 
oxaloacetate was previously discussed.  Forming mitochondrial acetyl-CoA is how free 
fatty acids are able to provide alternate fuel to cells.  The liver also generates another 
metabolic fuel, ketone bodies, which are able to be transported to other cells.  Though 
multiple tissues are capable of lipolysis, very few are capable of ketogenesis.  The next 
reaction, up-regulated by cAMP but down-regulated by insulin signaling, is a 
combination of a multiple steps which convert two molecules of acetyl-CoA to a ketone 
body, namely acetoacetate and 3-hydroxybutyrate. 
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 Although biochemical processes may take place in the blood, this is probably at 
an insignificant scale when compared to functional tissues.  The blood component of our 
model has the primary purpose of a transport system between the metabolic tissues.  The 
metabolites that are able to transport between tissues are glucose, lactate, free fatty acids, 
ketone bodies and alanine.  The hormones insulin and glucagon reside only in the blood 
component in this model.  Any effects due to the presence of insulin and glucagon are 
due to the inter-cell signaling of the binding of these hormones to cell surface receptors.  
Within the model, the blood concentrations of insulin and glucose directly affect the rate 
of certain reactions and also directly affect the synthesis and degradation of cAMP 
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although this process is also through inter-cell signaling.  Figure 4.3 shows the transports 






























Figure 4.3.  Reactions for Transport Across the Cell Membranes.  The 
corresponding rate of each reaction is described in the text. 
 Glucose enters the system from the gut via the portal vein, bringing a supply of 
blood from the gut to the liver.  The liver also receives another flow of blood through the 
hepatic artery.  The blood that flows through the hepatic artery and hepatic vein is that 
which connects the liver to the rest of the metabolic system.  As the portal vein only 
connect the liver with the gut, our model has only considered one type of blood, that 
which connects the liver with the muscle and fat tissue.  This simplification requires an 
alternate method of bringing digested glucose into the system and so this glucose is 
introduced directly to the bloodstream. 
This investigation of incorporating a detailed model of the glycogen regulatory 
circuit into a contextual metabolic framework focuses on the transition time from a 
feeding state to a post-absorptive, or fasted, state.  The time-dependent variable providing 
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food to the system, vfeed, was designed with three objectives:  1) the system be brought to 
a fed steady state for t < 0 so that initial values of the simulation are that of a fed state, 2) 
the fasting state be reproduced by a gradual decline of feeding as seen with a gradual 
absorption of food from the gut during digestion, and 3) this function, vfeed, be 
continuous.  To replicate a fed state, the system is brought to steady state with a constant 
flux of vfeed = kf where kf is currently defined as 0.5 mM/min.  To mimic the gradual 
decline of food intake during digestion, vfeed then follows a normal distribution curve with 
a mean of t = 0.  A standard deviation such that vfeed = 0.5 mM/min when t = 0 will make 
this two piece function continuous.  An absorption period of approximately 3 hours, or 
180 minutes, was desired to correspond with previous studies on absorption rates of food 
products from the small intestine of a rat ([21], [22]).  To achieve this, the quantity in the 
numerator of the exponent, (t – µ), was multiplied by a factor of 0.014 causing a stretch 
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Figure 4.4.  Feeding Flux, Fed to Fasted.  The feeding function, vfeed, is a time-
dependent, two-piece function to transition from a fed state with a constant flux 
for t < 0 and a gradual decline of flux for t ≥ 0.  Most absorption has taken place 
by approximately 3 hours. 
 
 
 While the liver membrane contains the insulin independent glucose transporter, 
GLUC2, fat and muscle tissue both contain GLUC4 transporters that are dependent on 
insulin.  The transport of glucose across the liver membrane, vtL1, is passive and so 
depends on the difference between the concentration of glucose inside and outside of the 
liver.  The transport of glucose across the membranes of fat and muscle tissue, vtF1 and 
vtS1 respectively, is modeled linearly with respect to the amount of blood glucose and is 
up-regulated by blood insulin levels. 
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 The liver and muscle both contain lactate, the end product of anaerobic glycolysis.  
This metabolite participates in the Cori cycle, the process in which glucose from the liver 
enters the muscle, lactate is formed and transported back to the liver to enter 
gluconeogenesis and form glucose.  As mentioned previously, the muscle is unable to 
produce glucose due to the lack of the enzyme glucose 6-phosphatase so the muscle 
assists in stabilizing glucose levels through the Cori cycle.     
 
2 2   [ _ ]tL tLv k B lac=  
3 3   [ _ ]tS tSv k M lac=  
 
During fasting and starvation, ketone bodies are formed as free fatty acids are 
broken down.  This occurs in the liver and these ketone bodies are transported to the 
muscle to be used as an alternate metabolic fuel so that the muscle does not require as 
much blood glucose and this glucose is reserved for other tissues unable to adapt to using 
alternate fuels. 
 
3 3   [ ]tL tLv k ket=  




Also during fasting and starvation, fats are released from the fat tissue and 
transported to the liver and other tissues where they are used as an alternate fuel source.  
The model disregards the transport of fats to the muscle as this tissue is already taking the 
alternate fuel source of ketone bodies.  Only fat transport into the liver is considered as 
fats also increase the rate at which amino acids are used as substrate for gluconeogenesis 
as well as providing an alternate fuel source for the TCA cycle.  The release of fats from 
fat tissue takes on a more complicated form than other metabolite transport and is down-
regulated by insulin. 
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Protein degradation is continuously occurs at all feeding levels but increases in 
response to the body’s need of glucose.  During fasting, this process is sped up to provide 
a source of substrate for gluconeogenesis.  The model assumes proteins have already 
been broken down to the amino acid building blocks and considers alanine as the main 
amino acid in this process.  Alanine is transported from the muscle to the liver and each 
transport is down-regulated by the presence of insulin. 
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 The model assumes a linear rate of decay for each metabolite and hormone 
present in the blood. 
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Since our model is concentrated on the liver’s role in metabolism, a brief sketch 
of the metabolic processes in the fat and muscle tissue are modeled.  The important role 
of fat tissue is that glucose is taken up by fat in an insulin-dependent manner and is stored 
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as triacylglycerol within fat tissue until blood glucose levels drop and these glucose 
stores are needed.  The transport of glucose into and free fatty acids from fat tissue were 
described in Section 4.3.2.  The only metabolites modeled for fat tissue are glucose 6-
















Figure 4.5.  Reactions Included in the Fat Component of the Model.  The 
corresponding rate of each reaction is described in the text. 
Each reaction within the model for processes that take place in fat tissue are all 
approximated using linear dynamics with respect to the appropriate substrate for the 
reaction.  As triacylglycerol is the storage form of glucose, each reaction increasing the 
formation of triacylglycerol is up-regulated by insulin signaling while the reaction that 
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As with the fat tissue, the muscle component of the model contains a backbone of 
the metabolic processes that occur in normal muscle tissue and each reaction is modeled 























Figure 4.6.  Reactions Included in the Muscle Component of the Model.  The 
corresponding rate of each reaction is described in the text. 
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An abbreviated pathway of glycolysis is modeled in the muscle portion of the 
liver.  This pathway, as is the glycogen regulatory circuit, in the muscle is very similar to 
that of the liver.  The muscle is not capable of gluconeogenesis due to the absence of 
glucose 6-phosphatase.  Because of this, the key metabolites of gluconeogenesis that 
were included in the liver were left out of the muscle model.  Glucose 6-phosphate was 
included because of its options to either be converted to glycogen or to move through 
glycolysis with pyruvate as an end product.   
 
1 1   [ _ 6 ]S Sv k M g p=  
 
- 1 - 1   [ _ ]S Sv k M glycgn=  
 
2 2   [ _ 6 ]S Sv k M g p=  
 
 
Pyruvate can either form lactate which can then be transported to the liver as part 
of the Cori cycle or form alanine, our representative of amino acids and proteins.  
Alanine is transported to the liver during fasting to provide substrate for gluconeogenesis. 
 
3 3   [ _ ]S Sv k M pyr=  
 
- 3 - 3   [ _ ]S Sv k M lac=  
 
4 4   [ _ ]S Sv k M pyr=  
 
 
Ketone bodies enter the muscle to provide alternate fuel.  In our model, these 
increase the rate at which alanine is degraded and transported from the liver.   
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- 4 - 4   [ _ ] [ _ ]S Sv k M alan M ket=  
 
_ _
   [ _ ]S dket S dketv k M ket=  
 
The roles of the muscle in our model include participation in the Cori cycle and 
protein degradation as well as a sink for alternate fuel in the form of ketone bodies.  
Greatly neglected is the use of glucose and these ketone bodies for energy through the 
TCA cycle. 
 
4.4 Detailed Local Model 
 The localized section of metabolism chosen for a more detailed investigation 
encompasses the mechanisms behind the activation and deactivation of hepatic glycogen 
synthase and glycogen phosphorylase.  Previously, it was mentioned that blood glucose 
levels regulate the amount of insulin and glucagon released into the bloodstream.  
Through binding to cell surface receptors and subsequent signal transduction, insulin and 
glucagon regulate cAMP levels with the cell.  The reduced version of the glycogen 
regulation circuit has cAMP directly affecting the rate of phosphorylation of GS and GP 
while the full circuit includes the intermediate enzymes which create a cascade of 































Figure 4.7.  Reactions Included in the Reduced Glycogen Regulatory Circuit.  
The corresponding rate of each reaction is described in the text. 
 
4.4.2 Full Glycogen Regulatory Circuit 
At the center of figure 4.6, the metabolites within the model that are involved in 
glycogen synthesis and degradation are shown.  Around these are the enzymes 
responsible for the regulation of the rate at which these processes occur.  Figure 3.1 also 
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Figure 4.8.  Reactions Included in the Full Glycogen Regulatory Circuit.  The 
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9 -   [ 1] [ ]  -    [ 1_ ]g a av k PP GPa k PP GPa=  
 
2
10 1 1   [ 2 2] [ ]  -   [ 2 _ _ 2] [ ]g gc gcv k R C cAMP k R C cAMP C−=  
 
2
11 2 2   [ 2 _ _ 2] [ ]  -   [ 2 _ 4] [ ]g gc gcv k R C cAMP cAMP k R cAMP C−=  
 
 
To test the detailed model of the glycogen circuit, this model was run to steady 
state and compared with the results published in [19].  Here, the fractional modification, 
or the percentage of activation through either phosphorylation or dephosphorylation, of 
the enzymes is compared in the glycogen circuit under the conditions of a fed state and a 
fasted state.  The variation between feeding states is depicted through the dissociation 
constant of GPa binding to glycogen synthase PP1.  vg9, which represents the net flux of 
the binding of GPa and PP1, equals zero at steady state.  From the resulting equation, 
representation of the corresponding dissociation constant is found. 
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9 -   [ 1] [ ]  -    [ 1_ ]  0g a av k PP GPa k PP GPa= =  
-
[ 1] [ ]








It has been shown that a significant amount of glycogen must be present for this binding 
to occur [23, 24].  To simulate a fed state in [19], a rate of  kd = 0.002 µM was used as 
there would be glycogen present to allow for PP1_GPa to accumulate at steady state.  
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 Figure 4.9.  Steady State Results of the Glycogen Circuit Model.  Figures in the  
left column (A, C, E) resulted from a simulation under fed conditions (kd = 
0.002 µM).  Figures in the right column (B, D, F) resulted from simulations 
under fasted conditions (kd = 2 µM).  These replicate previously published 
results in which the presence of glycogen affects the activation of glycogen 
synthase (curve a) with respect to the dosage of glucose, cAMP, glucose 6-
phosphate.  Glycogen phosphorylase (curve b), phosphorylase kinase (curve c) 
and the catalytic subunit of cAMP dependent protein kinase (curve d) are 
unaffected by the presence or absence of glycogen. 
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Figure 4.10.  Futile Cycling at Steady State.  These simulations also replicate 
previously published results in comparing the activation of GP, glycogen 
phosphorylase, with that of GS, glycogen synthase.  A reciprocal regulation is 
observed during the fed state (A, kd = 0.002 µM) while futile cycling occurs 
during fasting (B, kd = 2 µM). 






































Figure 4.11.  Futile Cycling at Various Levels of Feeding.  a – fed, little futile 
cycling present, g – fasted, a lot of futile cycling present. 
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Figure 4.12.  Fractional Modification of GS and GP Over Time.  The initial 
conditions for this simulation were found by running the isolated model of the 
full regulatory circuit steady state with glucose = 5 mM and glucose 6-phosphate 
at 0.1 mM.  At time = 0 minutes, glucose and glucose 6-phosphate were 
increased to 60 mM and .7 mM, respectively.  With kd = 0.2 µM, in a fasted 
state, the full regulatory circuit in isolation is able to replicate the results found 
in Cardenas that detail the effects of increased glucose on modification of GS 
and GP.  Curve a, GSa; curve b, GPa. 
 
4.5 Connecting the Models 
 Originally, cAMP was a direct regulator of the glycogen synthesis and 
degradation terms in the contextual model.  This model was changed to include GPa and 
GSa concentrations in order to be able to easily connect the detailed regulatory model 
with the contextual model and to still run each model in isolation from the other.  Recall 
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vL2 and vL-2 from section 4.3.1.  When the detailed model is not connected to the 
contextual model, the ‘whole-physiology’ model can be run with a constant amount of 
GSa and GPa and the local model can be run with prescribed amounts of glucose, glucose 
6-phosphate and cAMP.  This format allows for easy manipulation of the regulatory 
circuit to ‘cut out’ enzymes within the cascade or to add new enzymes to create a more 
complicated cascade.   
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Figure 4.13.  Steady State Comparison of Fractional Modification in Reduced 
and Full Circuits.  By modifying the rate constants which affect the 
phosphorylation of GS and GP, the steady state switch-like behavior in the 
reduced model is comparable to that of the full model.  Curve a, reduced model 













Results and Discussion: 
Model Integration and Optimization   
 
5.1 Overview 
In isolation, the full glycogen regulatory circuit and the reduced glycogen 
regulatory circuit were comparable in response to glucose, glucose 6-phosphate and 
cAMP levels.  These circuits were immersed into a ‘whole’-physiology model to 
investigate the optimization of the effects of the full glycogen regulatory circuit on the 
metabolic system.  The following model simulations will support the hypothesis that the 
architecture of the glycogen regulatory circuit stabilizes blood glucose levels by 
optimizing the combination of rates at which ingested glucose, glycogen and amino acids 
(with assistance from free fatty acids) are used as substrates for blood glucose. 
To understand the various stages of feeding, simulations were produced in which 
the system had a constant intake of ingested glucose, producing a ‘glucose-fed’ stage.  
Ingested glucose was then removed and the system relied on the next source of glucose 
substrate, glycogen, putting the system in a ‘glycogen-fed’ stage.  Next, glycogen was 
depleted and the system was put into a ‘ffa/aa-fed’ (free fatty acid/amino acid) stage of 
feeding in which alanine (an amino acid) was broken down to form glucose with free 
fatty acids used as an assisted energy source for this process.  There were no significant 
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differences between the simulations involving the full glycogen regulatory circuit and the 
reduced circuit. 
Time dependent simulations showed differences in select metabolite 
concentration levels during the transitional periods between feeding stages.  The full 
circuit allowed for a quicker response time in which glycogen was able to be stored or 
utilized during high and low blood glucose levels respectively.  This led to a more 
controlled balance among ingested glucose, glycogen and amino acids in stabilizing 
blood glucose levels.   
 
5.2 Initial Fasting Simulation 
 The first objective of the contextual model was to mimic the observed behavior of 
key metabolites and regulators as was discussed in Section 4.3.  The results of a fasting 
simulation are shown in Figure 5.1.  This simulation started with initial conditions from a 
fed state.  There are two periods of transition in this simulation, one at t = 0 in which the 
system shifts from relying on ingested glucose to use of hepatic glycogen stores 
accumulated during feeding.  Blood glucose levels exhibit damped oscillations until 
about 400 minutes.  We will discuss later how blood glucose levels for the fasted state are 
lower than those for the fed state.  The second transition period occurs at about t = 1700 
when liver glycogen is depleted.  Here the system adapts again to increasingly rely on fat 
reserves to generate energy for glucose synthesis from amino acids through hepatic 
gluconeogenesis.  We again see the adjusted level of blood glucose to be lower than that 
of a fed state and also a fasted state.  Other metabolites exhibit a complex range of 
responses to the adaptive changes needed to maintain critical blood glucose levels during 
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these bioenergetic transitions.  Glycogen is depleted during the fasting state while blood 
concentrations of free fatty acids and ketone bodies both rise during each period of 
transition.  Insulin and glucagon levels change inversely, in response to and to maintain 
the observed changes in blood glucose concentrations.  This simulation was run with the 
full glycogen regulatory circuit included.  Figure 5.2 provides a comparison between a 
simulation run with the full glycogen regulatory circuit and one with the reduced 
regulatory circuit. 
 

























Figure 5.1.  Initial Simulation of Relative Concentrations of Select Metabolites 
During Fasting.  The model captures the dynamic behavior of selected 
metabolites and hormones during the fasting period. The system, initially in a 









































Figure 5.2.  Comparison of System Responses to Fasting Using the Full or 
Reduced Circuits. (full, a; reduced, b)  While some differences arise, the relative 
behavior of metabolites and hormones follow the observed behavior reported in 
the literature [10], as can be verified by comparing Figure 5.2 to Figure 4.1. 
 
 
5.3 System Behavior During Various Feeding Stages 
 The model results support the hypothesis that glycogen regulatory circuitry is 
designed to efficiently store and utilize glycogen during transitory feeding states, 
particularly in the refeeding state.  As the conversion of glucose to and from glycogen 
and amino acids is a continuous and intertwined process, it is unrealistic to consider 
separate situations in which glucose is solely converted from glycogen or solely 
converted from amino acids and fats.   During fasting, the period of dependence on liver 
glycogen overlaps that of dependence on gluconeogenesis. In fact, these processes appear 
to approach their respective asymptotes, with some futile cycling occurring during the 
transitions. However, by looking at ingested glucose, glycogen and amino acids as 
independent substrates for glucose, one can determine the ability of the system to 
stabilize glucose levels from these individual sources. 
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For this investigation, the body was considered to be in one of three bioenergetic 
states:  a fed state in which substrates for blood glucose are provided through digestion of 
food (glucose-fed); a fasted state in which digestion has ceased and the maintenance of 
blood glucose levels is dependent upon glycogen that has been stored in the liver 
(glycogen-fed); and a starvation state in which hepatic glycogen stores have been 
essentially depleted and amino acids are being broken down with the assistance of fats (as 
an energy source) and are the substrate for blood glucose (Free Fatty Acid/Amino Acid-


































Figure 5.3.  Simulation Results: Blood Glucose Levels During the Three 
Feeding States.  These levels are highest when the system receives a constant 
intake of glucose through digestion and lowest when the system is in a state of 
starvation, relying on the FFA and AA stores to make glucose.  Little difference 
is seen when comparing the simulations with the full glycogen circuit with those 
obtained with the reduced circuit. 
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investigated in order to yield insights into the behavior of the system as a whole, and the 
sensitivity of the system to modification of the glycogen control circuitry: full glycogen 
circuit and a reduced glycogen circuit. 
 An important feature of the metabolic system is its ability to maintain blood 
glucose levels.  Figure 5.3 shows the blood glucose levels obtained from simulations of 
the three feeding stages.  Blood glucose levels drop as the system progresses through the 
various stages.  There is little difference between the simulations containing the full 
glycogen regulatory circuit and the reduced circuit with respect to the blood glucose 
concentrations achieved in the three states. There are, however, significant differences in 
the dynamics of the transitions through each of the states (see below) Furthermore, 
though differences predicted by the model are probably biologically insignificant, it is 
worth noting that the full glycogen regulatory circuit keeps blood glucose levels closer to 
the desired level of 8 mM.  The insulin/glucagon switch in response to changing glucose 








































Figure 5.4.  Simulation Results: Glycolytic and Gluconeogenic Intermediate 
Levels During the Three Feeding Stages.  The blue and maroon bars represent a 
glucose-fed stage and are notably increased for the metabolites involved in both 
glycolysis and gluconeogenesis.  Cytosolic oxaloacetate (oa_c), the only 
metabolite here involved in gluconeogenesis but not glycolysis, is increased in 
the glucose-fed stage due to excess glucose cycling back.  The main difference 
between the two models is that the level of oxaloacetate is controlled by the 
model with the full glycogen regulatory circuit.  This is due to the excess 
glucose being stored as glycogen rather leaking through the system.  (g6p, 




 During the glucose-fed state (blue and maroon bars in Figure 5.4), the 
concentrations of metabolites involved in glycolysis, specifically glucose-6-phosphate 
(g6p), phosphoenolpyruvate (pep), pyruvate (pyr) and lactate (lac), are raised due to the 
excess of glucose in the system.  While cytosolic oxaloacetate (oa_c) is not involved in 
glycolysis, its level is also increased during a glucose-fed state due to the excess glucose 
fed into the TCA cycle and then distributed back through the gluconeogenic pathway.  
The levels of cytosolic oxaloacetate are higher in the simulation with the reduced 
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glycogen regulatory circuit than the full circuit, most likely due to the ability of the 
system with the full circuit to store glycogen at a faster rate.  This will be discussed more 
later. 
Metabolites in the gluconeogenic pathway, phosphoenolpyruvate (pep), pyruvate 
(pyr) and cytosolic oxaloacetate (oa_c) are slightly raised in the FFA/AA-fed state as 







































Figure 5.5.  Simulation Results: TCA Cycle Intermediate Levels During the 
Three Feeding States.  The behavior in Figure 5.4 is supported here by 
examining the levels of the metabolites found in the TCA cycle.  In the glucose 
fed stage (the blue and maroon bars) citrate, alpha-ketoglutarate (aK) and malate 
have lower concentration levels in the model with the full glycogen regulatory 
circuit due to excess glucose being funneled into storage as glycogen.  The 
concentration levels of mitochondrial acetyl-CoA (acet_m) are raised in the 




 The differences observed in Figures 5.4 and 5.5 are caused by the different 
amounts of glycogen and blood glucose present.  The difference in these concentration 
levels are initiated by the glycogen regulatory circuit and the reaction time in which 
glycogen synthase is activated.  This reaction time will be discussed further with a time-
dependent simulation.  While the system is in a state of high blood glucose levels, the full 
glycogen regulatory circuit fully activates glycogen synthase while the reduced circuit 
only partially activates glycogen synthase (Figure 5.6). 
 
 










































Figure 5.6.  Simulation Results: Fractional Modification of Glycogen Synthase 
and Glycogen Phosphorylase During the Three Feeding States.  Many of the 
differences in concentration levels seen in previous figures are a result of the 
amount of active glycogen synthase present in the models.  For the glucose-fed 
stage, glycogen synthase is fully activated by the full glycogen regulatory circuit 





The purpose of muscle tissue in this model is to utilize blood glucose and act 
purely as a sink.  Further development of this model will capture the processes by which 
amino acids are extracted from the muscle and transported to the liver to make glucose.  
Fat tissue in this model utilizes and stores glucose and releases fats when blood glucose 
levels are low that will be transported to the liver to undergo lipolysis.  As the pathways 
of these tissues are simplified, Figure 5.7 shows that the metabolic concentration levels 
mimic the levels of blood glucose.  Figure 5.8 verifies that in spite of this simplification, 
expected behavior of an inverse relationship between blood glucose levels and the levels 
of fats and ketones is captured by this model. 
 
 





































Figure 5.7.  Simulation Results: Select Concentrations in Fat and Muscle 
Tissues During the Three Feeding States.  Highest levels are observed in the 
glucose-fed system due to excess glucose.  These mimic the levels of blood 









































Figure 5.8.  Simulation Results: Lipolysis Levels During the Three Feeding 
States.  Fats assist in regulating blood glucose levels but have the dangerous side 
affect of higher ketone body levels.  The activity of lipolysis increases as the 
system transitions from one feeding stage to another.  (palm, palmitate; 
palmCoA, palmitate-CoA; B_ffa, blood free fatty acids; ket, ketone bodies; 




 A look at the time-dependent behavior of glycogen as the system is reaching a 
steady state (Figure 5.5 B) in a glucose-fed environment shows that a steady state is not 
reached for the glycogen concentration.  A time series for the net flux of glycogen 
synthesis (Figure 5.5 D) revealed that this reaction has reached equilibrium and that the 
net flux is positive resulting in a growing concentration of glycogen  Other variables were 
observed and glycogen was the only one for which a steady state was not reached.   For 
the fasted simulations, the initial condition of glycogen is chosen arbitrarily and is the 
same for both the full and reduced models.  It is important to note that the full model 
(black) stores glycogen at a higher rate than the reduced model (orange).  This is a direct 
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Figure 5.9.  Values of Glycogen and Net Glycogen Synthesis for a Glucose-Fed 
Steady State.  The amount of glycogen is significantly higher in the full model 
than in the reduced in the fed steady state, figure A.  However, observation of 
glycogen levels over time, figure B, reveal that glycogen is not in a true steady 
state.  Figures C  and D show the levels of net glycogen synthesis, respectively.  
Figure C shows that net glycogen synthesis is increased in the model with the 
full circuit and Figure D shows that this flux is at equilibrium. Thus, the 





5.4 Time-Dependent Simulations:  Monotonically Increasing Blood Glucose 
Levels 
 The main difference between the full and reduced glycogen regulatory circuits 
discovered through the investigation above was that the model with the full regulatory 
circuit was capable of storing more glycogen.  A system efficient in storing glycogen as a 
source of glucose substrate while in a fed stage can be beneficial to a system by providing 
the means of stabilizing blood glucose levels during a post-fed or post-absorption stage.  
To investigate this difference of the amount of glycogen storage, time-dependent 
simulations were run.  First, the transition of the system from a starved state to a fed state 
was simulated by starting blood glucose at a low level and forcing this concentration to 
increase over time.  This was done in the model by bring the system to a fed quasi-steady 
state while initializing blood glucose to have a concentration of 0 mM.  The rate at which 
blood glucose increased was kept constant at [ ] 0.01d Bgluc
dt
= .  This behavior for blood 
glucose is seen in Figure 5.10 a while the resulting behavior of glycogen levels is seen in 
Figure 5.10 b.  The glycogen is quickly used up in both simulations as blood glucose 
levels are detrimentally low.  Once blood glucose levels have (artificially) increased and 
surpassed the critical concentration level of 8 mM, the system shifts from utilizing 
glycogen to storing glycogen.  Once again, the simulation with the full glycogen 
regulatory circuit stores more glycogen and it appears that this is due to the system 





Figure 5.10.  Time-Dependent Simulation:  Glucose and Glycogen Levels. 
Glucose has a constant feeding rate.  Glycogen is depleted and then starts to 
build after glucose reaches a critical level (8 mM) at which the insulin/glucagon 
switch is activated.  The model with the full circuit stores more glucose as it 
initiated glycogen storage more rapidly. 
 
 
 This glycogen utilizing/storing switch that occurs in the system, as a result of the 
glucagon/insulin switch discussed earlier, affects the amount of glycogen stored by 
controlling the rates of glycogen synthesis and degradation.  It is shown in Figure 5.11 
that the behavior of insulin and glucagon blood levels (a and b respectively) are very 
similar when comparison the simulations with the full glycogen regulatory circuit and the 
reduced circuit.  This switch-like behavior of insulin and glucose is shown in relative 
comparison to blood glucose levels (c) which reach 8mM at around t = 800.  While there 
is minimal difference in the responsive behavior of insulin and glucagon, there is a 
significant difference in the timing at which glycogen synthase is activated.  Figure 5.11 
d compares the relative levels (magnified 15x) of active glycogen synthase (GSa) for  





















































































































Figure 5.11.  Simulation Results:  Insulin and Glucagon Levels Compared to 
Glycogen Synthase Activation.  Figures a and b compare levels of insulin and 
glucagon respectively between the models with the full regulatory circuit and 
the reduced circuit.  Results are shown from the model with the full regulatory 
circuit in figure c demonstrating the switch-like behavior of these two hormones 
occurring in response to blood glucose levels increasing.  Though insulin and 
glucagon levels are similar in each model, figure d shows a significant 
difference in the activation of glycogen synthase resulting in the greater buildup 
of glycogen in the model with the full regulatory circuit.  The activation switch 
for glycogen synthase is quicker causing a higher initial rate of glycogen 
synthesis. 
 
each circuit along with the corresponding glycogen levels.  Though both models appear 
to activate glycogen synthase and thus build glycogen at approximately the same time (t 




the reduced circuit resulting in more glycogen stored.  This difference in the rate of 
synthesis is evident between t = 800 and t = 1100 where the rate of synthesis appears to 
become equal.  This lends support to the idea that the glycogen regulatory circuit is vital 
to maintaining precise transition for the system during perturbation. 
Heatmaps will be used to investigate this difference in the rate of glycogen synthesis 
as well as other rates of select processes in the system.  Heatmaps are generated using an 
array of colors to correspond to the various levels of flux in the system.  The assigned 
colors for these heatmaps are specified in Figure 5.12 with blue corresponding to a value 
of -5, orange corresponding to a value of 0 and red corresponding to a value of 2.  While 
some heatmaps will show the actual level of flux for a reaction, some heatmaps will be 




-5 -4 -3 -2 -1 0 1 2
 
Figure 5.12.  Color Bar Scale for Flux Heatmaps.  A series of heatmaps will be 
presented in which the amount of flux for select processes throughout the system 
are graphically represented by a color coded map.  The color bar above gives the 
scaling used in most color maps, or heatmaps, with orange corresponding to a 
value of 0, red corresponding to a value of 2 and blue corresponding to a value 
of -5. 
 
The first heatmap, shown in Figure 5.13, displays the various fluxes involving 
glucose 6-phosphate.  This metabolite is involved in many processes and acts as an 
intersection connecting various metabolic pathways.  Glucose 6-phosphate is also the 
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only metabolite from which glycogen can be synthesized.  As seen earlier, this occurs 
through other intermediate metabolites (glucose 1-phosphate and UDP-glucose) which 


















Figure 5.13.  Simulation Results: Heatmap for Glucose 6-Phosphate Flow.  
Glucose 6-phosphate is involved in multiple pathways in the system.  This 
heatmap is a result of a simulation for the model with the full glycogen 
regulatory circuit and compares the total rate of change for glucose 6-phosphate 
(row 1) with the net rates of change for the separate pathways of glycogen 
synthesis (row 2), glucose production (row 3) and gluconeogenesis/glycolysis 
(row 4).  It is easily seen that in the beginning of the simulation, where blood 
glucose levels are low but rising and glycogen is still present, the dominate 
direction of flow is from glycogen to glucose 6-phosphtate to glucose.  In the 
latter stages of this simulation, the system has settled into a pattern of glucose 6-
phosphate being formed from glucose and then being processed into glycogen. 
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change for glucose 6-phosphate ( 1 2 3 1 2 3
[ 6 ]
L L L L L L
d g p
v v v v v v
dt − − −
= + + − − − ) while the 
remaining rows show the net rate of change for the three bidirectional pathways 
( 1 1[ 6 ] [ ] :  L Lg p gluc v v−→ − ; 2 2[ 6 ] [ ] :  L Lg p glycgn v v−→ − ; 3 3[ 6 ] [ ] :  L Lg p pep v v−→ − ). 
Extending this investigation to the entire fluxome (collection of fluxes) of the 
liver allows for a more complete understanding of the dynamics of the system during a 
transitional feeding stage.  The processes for the liver are detailed in Table 5.1 and the 
fluxes for these processes are portrayed in a heatmap in Figure 5.14.  Like the previous 
figure for the flow of glucose 6-phosphate, this figure is taken from simulation results for 
the model with the full glycogen regulatory circuit.  Two major shifts occur, the first 
being at the beginning of the simulation and the other at around t = 800.  The first shift is 
due to the adjustment of the system to current feeding condition.  The initial conditions 
were determined from a running the system to a quasi-steady state.  The second major 
shift, around t = 800, occurs after glucose has reached the critical value of 8 mM and the 
insulin/glucagon switch has occurred.  A detailed description follows of the information 
this fluxome heatmap contains.   
When glycogen is still present in the system (t < 350), the rates of glycogen 
degradation and the conversion of glucose 6-phosphate to glucose are increased as 
glycogen is being used as a source of glucose substrate.  Glycogen is nearly depleted for 
350 < t < 800 and the system displays many signs of being in a low glucose state.  During 
this time, glycogen synthase is almost entirely in the inactive state while glycogen 
phosphorylase is in an active state, as seen in Figure 5.15.  The rates of glycogen 
synthese (vL2) and degradation (v-L2) are both low as little active GS is present and little 
glycogen is present for active GP to convert to glucose 6-phosphate.  While some futile  
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Figure 5.14.  Time-Dependent Simulation:  Heatmap for Liver Fluxes, Full 
Circuit.  This heatmap detailed the fluxome for the liver during a transition from 
low blood glucose levels to high blood glucose levels.  Two major shifts are 
seen in the fluxome, the first due to an adjustment of the system to low blood 
glucose levels, the second due to glucose reaching a critical level of 8 mM 
causing the system to shift into a well-fed state.  The text gives a detailed 
description of the fluxome behavior for the system.  The corresponding rate of 
each reaction is described in the text and also can be found in the appendix. 
 
cycling occurs, it is kept to a minimum, conserving energy, as little glycogen is being 
made due to this low level of active glycogen synthase.    A bidirectional flow occurs 
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between glucose 6-phosphate and phosphoenolpyruvate and from the heatmap it is 
clearly seen that the dominant direction of this flow is from phosphonenolpyruvate to 
glucose 6-phosphate as v-L3 is greater than vL3.  These metabolites are in both pathways 
of glycolysis (converting glucose to energy) and gluconeogenesis (converting amino 
acids to glucose with the assistance of fats). The conversion of phosphoenolpyruvate to 
glucose 6-phosphate being more prominent indicates that the level of gluconeogenesis is 
greater that that of glycolysis while the system is in a state of low glucose levels.  The 
fluxes for other process involved in gluconeogenesis (vL11, vL12, vL13, vL20 and v-L21) are 
active during this time.  Fluxes for process involved in the TCA cycle (vL8, vL9, vL10, v-L11) 
are decreased during a time of low glucose levels as there is little substrate for this cycle 
provided from glucose.  The rates of lipolysis (vL17, vL18) and ketogenesis (vL19) are also 
increased in the simulation corresponding with the increased breakdown of fats that 
occurs in order to provide the necessary energy to convert amino acids to glucose via 
gluconeogenesis.  Two interesting questions that arise are why are fats unable to be used 
in place of glucose to provide energy for the cell and why are fats themselves unable to 
be converted to glucose?  While this thesis does not answer these questions, this model 
could be used in an attempt to do so.   
This heatmap displays the major shift in the fluxome as the system transitions from a 
low glucose state to a fed state (approximately t = 800).  Conversion between glucose and 
glucose 6-phosphate appears to occur at comparable rates.  With glucose levels above 8 
mM, more glucose should be converted to glucose 6-phosphate rather than from glucose 
6-phosphate.  Futile cycling for the synthesis and degradation of glycogen increases as  
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Figure 5.15.  Time-Dependent Simulation:  Active Glycogen Synthase and 
Active Glycogen Phosphorylase Levels.  While active glycogen phosphorylase 
levels are similar between the two simulations, there is a significant difference 
in timing for which glycogen synthase becomes activated.  The switch reacts 
more quickly for the model with the full glycogen regulatory circuit, allowing 
for glycogen to be made more efficiently when glucose levels reach the critical 
point of 8 mM. 
 
both fluxes increase (vL2 and v-L2).  The synthesis of glycogen clearly occurs at a greater 
rate indicating a positive net storage of glycogen.  Glycolysis rates have increased (vL3, 
vL4, vL5) as well as activity of the TCA cycle (vL6, vL8, vL9, and vL10) and lipogenesis (vL14, 
vL15, vL16).  The only questionable shift for fluxes in this simulation is for the fluxes 
involved in gluconeogenesis (vL11, vL12, vL13, vL20 and v-L21).  While those pertaining to the 
breakdown of amino acid alanine (vL20 and v-L21) for the carbon substrate in 
gluconeogenesis are decreased during a state of high glucose levels, the remaining fluxes 
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(vL11, vL12, and vL13) have increased.  Some of this subtrate is cycled back through the 
TCA cycle via vL4 but some is also converted back to glucose and accounts for why vL1, 
and v
-L1 are approximately equal and the net synthesis of glucose from glucose 6-
phosphate is approximately 0 during a time of high glucose levels.  While this appears to 
be inconsistent with known behavior of metabolism for a system with high blood glucose 
levels, this should not have an affect on the activity of glycogen storage and degradation. 
















































Figure 5.16.  Time-Dependent Simulation:  Heatmap for Liver Fluxes, Reduced 
Circuit.  This heatmap is very similar to that in Figure 5.14 for the simulation 
with the full glycogen regulatory circuit.  See text for a full description. 
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This simulation was repeated with the reduced glycogen regulatory circuit.  The 
resulting heatmap for the hepatic fluxome is shown in Figure 5.16 and is nearly 
indistinguishable from the heatmap for the fluxome with the full regulatory circuit.  In 
order to compare the fluxomes from these simulations, a ratio was created of the fluxome 
from the full circuit model to the fluxome of the reduced circuit model and displayed 
using a logarithmic scale, resulting in Figure 5.17.  Values of 0 in this heatmap 
correspond to ratios of 1 meaning that there is no difference between the fluxome level of 
that process in the full circuit model and the reduced circuit model.  In the beginning, 
many flux levels are lower in the full circuit model than in the reduced circuit model as 
evident by the lighter shades of orange in the heatmap for t < 200.  This could be 
accounted for by the glycogen being depleted at a slightly faster rate in the reduced 
circuit model (see Figure 5.10) providing more substrate for these processes.  The other 
(quite) notable difference in these fluxomes is the rates of glycogen synthesis and 
degradation.  For t < 800, the rate of glycogen degradation is comparable but the rate of 
glycogen synthesis is greater in the reduced circuit model than in the full circuit model 
suggesting a greater amount of futile cycling in the former.  If an extreme deficit of blood 
glucose exists, futile cycling could be detrimental to the system by using unnecessary 
energy.  When glycogen is nearly depleted (400 < t < 800) both rates are lower in the full 
circuit model than in the reduced circuit model.  As these processes are never fully 
stopped, some futile cycling occurs at all times but for t < 800 this futile cycling occurs at 
a greater (and possibly non-optimal) rate for the reduced circuit model.  Once blood 
glucose levels reach the optimal value of 8 mM (at approximately t = 800), the full circuit 
now shifts to having a greater level of futile cycling as both rates of glycogen synthesis 
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and degradation are greater than those in the reduced circuit model seen by a darker 
shade of red corresponding to a positive value.  The increase of the glycogen synthesis 
flux is due to the activation of glycogen synthase (which occurs earlier in the full circuit 
model).  Glycogen phosphorylase is still activated around t = 800 (see Figure 5.15, note 
the glycogen phosphorylase is active for a longer period in the full circuit model 
simulation) resulting in this increase in futile cycling. 
















































Figure 5.17.  Heatmap of the Ratio of Liver Fluxes, Full to Reduced.  The 
largest difference observed in the liver fluxes is between glycogen synthesis and 
glycogen phosphorylase.  Activity for both fluxes increased in model with full 




5.5 Time-Dependent Simulations:  Oscillatory Feeding Pattern 
 Previous simulations have shown that the architecture of the physiological 
glycogen regulatory circuit decreases response time in the activation/deactivation switch 
for glycogen synthase and glycogen phosphorylase during transitory feeding periods.  
The typical human experiences a periodic feeding function by digesting three meals  










Figure 5.18.  Oscillatory Feeding Function.  To model a periodic feeding pattern 
the rate at which glucose is ingested is set to   .25cos(.01 )  .25feedk t= + , shown 
by the blue dashed line.  This feeding function is shown in comparison to the 
feeding function used to model a fasting period (see figure 5.1) in which 





















 and 0.5fk = . 
 
 
spaced throughout a day.  This next simulation uses an oscillatory feeding function 
(   .25cos(.01 )  .25feedk t= + ) to mimic this behavior of a periodic ingestion of glucose.  
Figure 5.18 gives a plot of this feeding function. 
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Figure 5.19.  Oscillatory Feeding Simulation:  Glucose and Glycogen Levels.  
The full regulatory circuit keeps glucose levels closer to desired 8 mM level (a).  
Glycogen is seemingly preserved in model with full circuit (b). 
 
The differences in blood glucose levels in Figure 5.3 (steady state blood glucose 
values for the three feeding stages) were not considered to vary greatly between the two 
models.  Creating a pattern of oscillatory feeding for the system suggests that these 
differences observed throughout the system may enable a better stabilization of blood 
glucose levels by regulating the level remain near the value of 8 mM (see Figure 5.19 a).  
In figure b, there is a similarity in the rate of glycogen degradation for the two models but 
an obvious increase of glycogen synthesis for the model with the full circuit. 
Figure 5.20 shows blood glucose levels along with a heatmap for liver fluxes 
corresponding to the glucose levels for oscillatory feeding for the model with the full 
glycogen regulatory circuit.  It is again verified that this system is driven by glucose in 
that most reactions are reduced when blood glucose levels are low with the exception of 
glycogen degradation, to stabilize glucose levels, and the breakdown of amino acids for 
making glucose via gluconeogenesis. 
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Figure 5.20.  Oscillatory Feeding Simulation:  Heatmap for Liver Fluxes, Full 
Circuit, With Glucose.  Fluxes are shown (a) in relation to blood glucose levels 
(b).  During times when blood glucose is less than 8 mM, most reactions are 
reduced with the exception of glycogen degradation (v
-2) and the breakdown of 
amino acids for gluconeogenesis (v20). 
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Figure 5.21.  Oscillatory Feeding Simulation:  Glycogen Synthase and Glycogen 
Phosphorylase Activity.  As with the previous feeding pattern, little difference is 
seen in the glycogen phosphorylase levels (b) between the two regulatory 
circuits.  Glycogen synthase, however (a) varies in both the reaction time of 
activation and also the level of activation. 
 
The levels of activated glycogen synthase were observed to be grossly different 
between the model with the full circuit and that with the reduced circuit during the steady 
state simulations for the various feeding stages (Figure 5.6).  The previous time-
dependent simulation showed that the reaction time of activation was quicker in the 
model with the full glycogen regulatory circuit but the levels of activated glycogen 
synthase were comparable.  In this simulation with an oscillatory feeding pattern, both 
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the quicker reaction time of activation and the higher level of active glycogen synthase 
are observed in the model with the full circuit (Figure 5.21).  As before, glycogen 
phosphorylase shows little difference between the two models. 
The heatmap in Figure 5.22 shows that the level of fat transport from fat tissue to 
the liver is greater in the model with the full glycogen regulatory circuit (vtF3 and vtL5).  It 
would seem reasonable to think that the model with the more active fat transport would 
also have a greater rate of ketone transport from the liver to the blood.  However, Figure 
5.23 shows this is not the case as ketone transport from the liver to the blood (vtL3) is 
lower in the model with the full circuit.  Figure 5.23 also shows that ketone body levels in 
the blood are higher in the model with the reduced circuit.  This suggests that the model 
with the full regulatory glycogen circuit is able to utilize more fats and amino acids while 
































































Figure 5.22.  Oscillatory Feeding Simulation: Heatmap of the Ratio of Blood 
Fluxes, Full to Reduced, With Glycogen.  Glucose direction switching (flux=0 
when blue).  Fat transport is higher in the model with the full glycogen circuit 
(vtF3 and vtL5) while ketone body transport from the liver to the blood is lower 
(vtL3).  
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Figure 5.23.  Oscillatory Feeding Simulation:  Blood Glucose, Glycogen and 
Ketone Bodies.  While the full glycogen regulatory circuit somewhat preserves 
glycogen and more tightly regulates glucose near the desired level of 8 mM, it 




















6.1 Meal Variation 
 To reduce the complexity of whole metabolism, this model focused on the intake 
of a strictly glucose meal.  A glucose meal provided an ideal environment to investigate 
the switching of glycogen regulatory enzymes as the activation of these enzymes is a 
result of regulation associated with blood glucose levels.  As previously mentioned, 
meals are a combination of carbohydrates, fats and proteins which are digested to 
glucose, free fatty acids and amino acids, respectively.  The current model includes 
concentrations of glucose, free fatty acids and amino acids in the blood so is capable of 
easily being modified to investigate a meal composed as a mixture of these digestive 
products.  As this model was built with a purpose of investigating a fasted state, certain 
transport mechanisms with the model would need modified to more accurately depict the 
switching of feeding states.  For example, the fat tissue component within the model 
allows uptake of glucose from and free fatty acid release to the blood but neither of these 
processes are reversible.  To accurately model the uptake of free fatty acids from a meal, 
the transport mechanism of free fatty acids across the fat tissue membrane will need to be 
made bidirectional. 
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 Only one size of meal was considered in this investigation when bringing the 
system to a fed steady state.  With a strictly glucose meal, the size of meal can easily be 
modified within the function vfeed.  Timing of meals is another variable to be considered 
when looking at glucose metabolism.  This investigation focused on having initial 
conditions from a fed state and looking at the fasting period after this one meal in order to 
increase understand of the transition from a fed to fasted state.  Another transition period 
of interest is that of moving from the fasted state to a fed state.  The mechanisms 
necessary to stabilize blood glucose levels during this type of transition may vary 
depending on the size and timing of the second meal.  With some modification, this 
model can be used to investigate variations of meals such as meal composition, meal size 
and timing of meals 
 
6.2 Connecting More Subsystems 
 This thesis introduces the inclusion of a detailed model of the glycogen regulatory 
circuit into a whole-physiology, contextual model.  Numerous mathematical models of 
specific pathways within the metabolic system have been proposed in the literature.  
Continuing with this model by including more detailed models of specific pathways can 
lead to a more accurate model depicting the role of various pathways and metabolites 
within the whole metabolic system. 
 
6.3 Transcriptional Regulation 
 Regulation mechanisms included in this model were allosteric and hormonal in 
nature.  The only enzymes explicitly modeled were those of the glycogen regulatory 
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circuit.  These enzymes provided a protein layer to this model.  mRNA transcripts 
regulate the amount of proteins, in this case enzymes, formed thus regulating the level of 
enzyme activity.  The technology of today allows for the mass collection of data from 
experiments measuring the level of mRNA transcripts under specific conditions, such as 
fed and fasted conditions.  With slight modification, this model can be used to investigate 
the role of transcriptional regulation in the glycogen regulatory circuit as well as the 
allosteric regulation that occurs in activating the enzymes. 
 
6.4 Fluxomics 
 The technological advances of the day also allow for the collection of in vivo data 
about fluxes within the system.  This has been done using nuclear magnetic resonance 
(NMR).  As shown with the heatmaps depicting the various fluxes within the model, 
observing the fluxome, the collections of fluxes of a system, can provide important 
information not observed by looking at concentrations alone.  This model can be further 
enhanced by comparing the fluxes from the model with experimental data in the literature 
for metabolic fluxes.  This experimental data may be helpful in suggesting a more 
accurate parameter set.  This model and NMR experimentation may be useful in 
identifying certain metabolic conditions through the fluxome. 
 
6.5 Liver Glycogen and Muscle Glycogen 
 Though the regulatory circuits for activation of glycogen synthase and glycogen 
phosphorylase are very similar between liver and muscle, some important functional 
differences exist.  Protein phosphatase-1 (PP1) dephosphorylates phosphorylase kinase, 
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glycogen synthase and glycogen phosphorylase in both the liver and the muscle (Fong).  
While other phospatases are capable of catalyzing these reactions, only PP1 was taken 
into consideration in the model for simplification purposes.  Studies have shown that an 
inhibition of PP1 activity on hepatic glycogen synthase is due to the presence of glycogen 
phosphorylase [24].  This mechanism is modeled by the binding of GPa and PP1 in the 
liver, inactivating this PP1 in relation to glycogen synthase.  While this inhibition has not 
been seen in the muscle, a different mechanism of inhibition has been identified.  In the 
muscle, inhibitor-1 inactivates PP1 which affects the dephosphorylation rate of all 
enzymes in the cascade.  The current model contains muscle glycogen but the synthesis 
and degradation of this glycogen has been turned off while investigating liver glycogen.  
Further study of this model can easily include the differences in behavior of synthesis and 
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9 9   [ ]L Lv k citrate=  
 
10 10   [ ] L Lv k aK=  
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  [ _ ]
ep
L L ep ep
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- 11 - 11   [ ]L Lv k malate=  
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BLOOD RATES (Transport and Decay): 
 
1 1   ([ _ ] -  [ ])tL tLv k B gluc gluc=  
 
2 2   [ _ ]tL tLv k B lac=  
 
3 3   [ ]tL tLv k ket=  
 
5 5   [ _ ]tL tLv k B ffa=  
 
10
6 6 10 10   [ _ ] 
  [ _ ]
en
Dins
tL tL en en
Dins
k







1 1 12 12
[ _ ]
   [ _ ] 1  
  [ _ ]
ep
tF tF ep ep
Dins
B ins
v k B gluc
k B ins
 





3 3 9 9
2
   [ _ ]  
  [ _ ]
en
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tF tF en en
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k







1 1 13 13
[ _ ]
   [ _ ] 1  
  [ _ ]
ep
tS tS ep ep
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v k B gluc
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 
= + + 
 
 
2 2   [ _ ]tS tSv k B ket=  
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3 3   [ _ ]tS tSv k M lac=  
 
11
4 4 11 11   [ _ ]   
  [ _ ]
en
Dins
tS tS en en
Dins
k







   [ _ ]d Bgluc d Bglucv k B gluc=  
 
_ _
   [ _ ]d Bins d Binsv k B ins=  
 
_ _
   [ _ ]d Bglucgn d Bglucgnv k B glucgn=  
 
_ _
   [ _ ]d Bffa d Bffav k B ffa=  
 
_ _
   [ _ ]d Blac d Blacv k B lac=  
 
_ _
   [ _ ]d Bket d Bketv k B ket=  
 
_ _






1 1 14 14
[ _ ]
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  [ _ ]
ep
F F ep ep
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 
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1 1   [ _ 6 ]S Sv k M g p=  
 
- 1 - 1   [ _ ]S Sv k M glycgn=  
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2 2   [ _ 6 ]S Sv k M g p=  
 
3 3   [ _ ]S Sv k M pyr=  
 
- 3 - 3   [ _ ]S Sv k M lac=  
 
4 4   [ _ ]S Sv k M pyr=  
 
- 4 - 4   [ _ ] [ _ ]S Sv k M alan M ket=  
 
_ _
   [ _ ]S dket S dketv k M ket=  
 
 
HORMONAL GROWTH RATES: 
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1 1 2 2 3 3
[ 6 ]
   -   -     -    L L L L L L
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v v v v v v
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3 - 3 4 13
[ ]
  2  -  2  -    L L L L
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v v v v
dt
= +  
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4 5 - 5 6 7 21 - 21 20
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d pyr
v v v v v v v v
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= + + +  
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[ ]
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v v v v
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A.2 Rates and Equations for Glycogen Regulatory Circuit Model 
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B.1 Parameter Values for Liver Reactions 
 
 
Reaction Parameters  Reaction Parameters 




kL1 = 3 
kmL1 = 7.7  [25] 
ep1 = 10 
 
vL6 
kL6 = 1 
kmL6 = 0.22 [26] 
p2 = 1 
kp2 = 2 




-L1 = 4 
km-L1 = 1.3 [27] 
ep9 = 10 
 
vL7 
kL7 = 1 
kmL7 = 0.0204 [28] 
ki8 = 2 
vL2 
kL2 = 20 
kmL2 = .57 [29] 
 
vL8 
kL8 = 0.1 




-L2 =  20 
km-L2 = 1.4 [30] 
 
vL9 kL9 = 0.1 
vL3 
kL3 = 0.1 
kmL3 = .01 [31] 
ep2 = 10 
en1 = 10 
 




-L3 = .1 
km-L3 = 0.0034 [32] 
ep8 = 10 
en6 = 10 
 
vL11 
kL11 = 0.6 
ep5 = 10 
vL4 
kL4 = 2,  
kmL4 = 0.18 [33] 
ki13 = 2,  
ep3 = 10,  
en2 = 10 
 
v
-L11 k-L11 = 0.01 
vL5 
kL5 = 0 
kmL5 = .03 [34] 
 
vL12 
kL12 = 0.6 
ep6 = 10 




-L5 = 0.1 
km-L5 = 0.8 [35] 
 
vL13 
kL13 = 0.5 
ep7 = 10 
en5 = 10 
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vL14 
kL14 = 0.01 
ep10 = 10 
en7 = 10 
 
vL19 
kL19 = 0.01 
ep11 = 10 
en8 = 10 
vL15 
kL15 = 0.01 
p1 = 1 
kp1 = 0.5 
ki5 = 1 
 
vL20 kL20 = 0.2 
vL16 kL16 = 0.01 
 
vL21 
kL21 = 0.001 
en3 = 10 
kmL21p = 0.4 [36, 37] 
kmL21g = 4.3 [36, 38] 
vL17 
kL17 = 0.01 





-L21 = 0.2 
en3 = 10 
km-L21a = 21 [39] 
km-L21k = 0.22 [39] 
vL18 
kL18 = 0.01 
ki2 = 1 
 





B.2 Parameter Values for Blood Reactions (Transport, Decay and Feed) 
 
 




vtL1 ktL1 = 100  
 
vtF1 
ktF1 = 0.01 
ep12 = 10 
vtL2 ktL2 = 0.1 
 
vtF3 
ktF3 = 0.01 
en9 = 20 
vtL3 ktL3 = 0.1 
 
vtS1 
ktS1 = 0.01 
ep13 = 10 
vtL4 ktL4 = 0.1  vtS2 ktS2 = 1 
vtL5 ktL5 = 0.1  vtS3 ktS3 = 0.01 
vtL6 
ktL6 = 1 
en10 = 10 
 
vtS4 
ktS4 = 3 




vd_Bgluc kd_Bgluc = 0.01  vd_Blac kd_Blac = 0.01 
vd_Bins kd_Bins = 0.01  vd_Bket kd_Bket = 0.01 
vd_Bglucgn kd_Bglucgn = 0.01  vd_Balan kd_Balan = 0.01 






B.3 Parameter Values for Fat Reactions 
 
 





kF1 = 0.1 
ep14 = 10 
 
vF4 
kF4 = 0.1 
en12 = 10 
vF3 
kF3 = 0.2 
ep15 = 10 
 







B.4 Parameter Values for Muscle Reactions 
 
 




vS1 kS1 = 0  vS4 kS4 = 0.07 
v
-S1 k-S1 = 0  v-S4 k-S4 = 0 
vS2 kS2 = 0.02  vS5 kS5 = 0.5 
vS3 kS3 = 0.01  vS_dket kS_dket = 0.01 
v














B.5 Parameter Values for Glycogen Regulatory Circuit Reactions 
 
 





kg3 = 1200 [19] 
kmg3 = 0.0004 [19] 
 
vg6 
kg6 = 300 [19, 40]  
kmg6 = 0.005 [19, 41] 
s2 = .001 [19] 
) 
kgi = 10 [19] 
vg4 
kg4 = 300 [19] 
kmg4 = 0.0011 [19, 42] 
 
vg7 
kg7 = 1200 [19] 
kmg7 = 0.015 [19] 
vg5 
kg5 = 1200 [19, 43] 
kmg5 = 0.01 [19, 44] 
 
vg8 
kg8 = 3 [19] 
kmg8 = 0.00012 [19, 45] 
vg5, vg7, vg8 
s1 = 100 [19] 



















capkt = 0.00025 mM  PP2A = 0.000025 mM  g6pt = 0.7 mM 
It = 0.0018 mM  k11 = 0.000043 mM  kgi = 10 mM 
kt = 0.0025 mM  k22 = 0.0007 mM  s1 = 100 
pt = 0.07 mM  ki = 0.1 mM  kg2 = 0.5 mM 
st = 0.003 mM  campt = 0.01 mM  s2 = 0.001 







B.7 Parameter Values Pertaining to Non-Metabolite Regulators (Insulin, 
Glucagon and cAMP) 
 
 









vtS1, vtS4, vF1, 
vF3, vF4 
kDins = 1 * 10-6 
 




kDins2 = 0.75 * 10-6  vc1 kc1 = 1 kmc1 = 4 * 10-8 
v
-L1, vL3, v-L3, 
vL4, vL6, vL11, 
vL12, vL13, 
vL14 
kDglucgn = 4 * 10-8 
 
vc2 
kc2 = 1 * 10-5.5 
kmc2 = 1 * 10-6 
vL19 kDcAMP = 1 * 10-5.5 
 
vgc1 
kgc1 = 6 * 1010 
k
-gc1 = 1.3953 * 1015 
vins kins = 7 * 10-4 
 
vgc2 
kgc2 = 6 * 1010 
k
-gc2 = 8.5714 * 1013 
vIgluc 
k1ins = 6 * 10-4 
kmins = 8 
ni = 10 
 
vIgluc, vc1 ni = 10 
vGgluc 
k1glucgn = 5 * 10-9 
kmGlgn = 8 
ng = 10 
 








Matlab Simulation Code 
 




% which_loop = 'trnscrpt';      % compares 2 simulations, with different transcriptional 
regulation patterns (see par_transcripts.m) 
which_loop = 'circuits'; 
number_runs = 2;                % number of simulations to compare (only 1 or 2),  
norm_method = 0;     
run1_transcripts = 0;   % input which transcript data to use IF comparing transcripts 
run2_transcripts = 0;   % see transcript_vectors.m (let run2_transcripts=[3]  
reg_ko1 = 0;            %    and reg_ko2=2 in order to knockout GPa 
reg_ko2 = 0; 
 
%  LOOP for 1 or 2 simulations  
for num_simulation = 1:number_runs 
     
    % initialize 'trans' vector if comparing transcrpt reg. or initialize 
    %   which glycogen regulatory circuits to compare ('mut') 
    if which_loop == 'trnscrpt' 
        trans = 
transcript_vectors(run1_transcripts,run2_transcripts,reg_ko1,reg_ko2,num_simulation); 
    elseif which_loop == 'circuits' 
        trans = zeros(1,15);    % no transcriptional regulation 
        if num_simulation == 1 
            mut = 'red';         % Reduced circuit (orange output) 
 124 
        elseif num_simulation == 2 
            mut = 'ful';          % Full circuit (black output) 
        end 
    end 
     
    y0 = init_main;     % load initial conditions from init_main.m 
 
% 1st run -- to steady state under constant feeding 
    tmax = 100000;       
    run=1;      % determines what feeding level will be (see ode_blood.m) 
    options = odeset('AbsTol',10^-12,'RelTol',10^-12); 
    [t,y] = ode15s(@ode_main,[0 tmax],y0,options,run,trans,mut); 
    num_simulation 
 
% 2nd run -- see ode_blood.m for feeding pattern (~line 30 to 44) 
    y0 = y(end,:);      % save output from last run as updated init conds 
    y0(3)=300;    %glycgn, start at same glycgn concentration 
    tmax = 2000;2000;       % max time point  
    run=2;              % determines what feeding level will be (see ode_blood.m) 
    [t,y] = ode15s(@ode_main,[0 tmax],y0,options,run,trans,mut); 
 
% 3rd run -- REFEED with constant feeding 
    y0 = y(end,:);      % save output from last run as updated init conds 
    tmax = 500; 
    run=1;              % determines what feeding level will be (see ode_blood.m) 
    %[t,y] = ode15s(@ode_main,[0 tmax],y0,options,run,trans,mut); 
 
    if num_simulation==1        % save output for graphing 
        y1 = y;        t1 = t; 
    else 
        y2 = y;        t2 = t; 
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    end 
end 
 
%    GRAPHS  
 
% plot first run output 
[v_matLIVER1,v_matBLOOD1,v_matFAT1,v_matMUSCLE1] = 
plot_main(t1,y1,1,number_runs,trans); 
if number_runs==1       % close figures only used to compare 2 runs 
    figure(301);close;figure(302);close;figure(303);close; 
end 
 
% plot second run output and comparison graphs 
if number_runs==2 
    [v_matLIVER2,v_matBLOOD2,v_matFAT2,v_matMUSCLE2] = 
plot_main(t2,y2,2,number_runs,trans); 
    plot_compare_run(v_matLIVER1,v_matLIVER2,1); 
    plot_compare_run(v_matBLOOD1,v_matBLOOD2,2); 
    plot_compare_run(v_matFAT1,v_matFAT2,3); 




display('End of program') 
return 
 
C.2 Code for Initial Conditions (init_main.m, init_liver.m, init_glycogen.m, 




% Called by main.m 
% Initial conditions are grouped by tissue in separate init_*.m files and 
% brought together here to be loaded into one main intial condition vector 
 
function y0 = init_main() 
 
y0_liver = init_liver(); 
y0_blood = init_blood(); 
y0_fat = init_fat(); 
y0_muscle = init_muscle(); 
y0_glycogen = init_glycogen(); 





% Called by init_main.m 
 
function y0 = init_liver() 
 
gluc = 5; g6p = 10; glycgn = 10; pep = .001; pyr = 3; lac = 1; oa_m = .0002; 
acet_m = 7; citrate = .5; aK = 1; malate = 3; oa_c = .0004; acet_c = 6; 
malonyl = .3; palm = .3; palmCoA = .3; ket = .08; alan = .1;  
cAMP = 10^(-5.5); glutamate = .1; co2 = 0; 
 
y0 = [gluc; g6p; glycgn; pep; pyr; lac; oa_m; acet_m; citrate; aK;  
    malate; oa_c; acet_c; malonyl; palm; palmCoA; ket; alan; cAMP;  











capkt = par(27); kt = par(28); pt = par(29);  
st = par(30); PP1t = par(31); 
 
PP1 = 1*PP1t; PP1_GPa = .0*PP1t; 
PKb = kt; PKa = 0; 
GPa = 1*pt; GSa = st; 
R2C2 = capkt; C = 0; R2_C_cAMP2 = 0; R2_cAMP4 = 0; 
 





% Called by init_main.m 
 
function y0 = init_blood() 
 
B_gluc = 4; B_ins = 1 * 10^(-6); B_glucgn = 40 * 10^(-9);  
B_ffa = .3; B_lac = .2; B_ket = .08; B_alan = .1; sink = 0; 
 






% Called by init_main.m 
 
function y0 = init_fat() 
 
F_g6p = 0; F_acyl = 0; F_TG = 0; F_ffa = 2; 
 





% Called by init_main.m 
 
function y0 = init_muscle() 
 
M_g6p = 8; M_glyc = 100; M_pyr = .2; M_lac = .2;  
M_ket = .1; M_alan = .4; 
 
y0 = [M_g6p; M_glyc; M_pyr; M_lac; M_ket; M_alan]; 
return 
 
C.3 Code for Parameter Values (par_liver.m, par_glycogen.m, par_blood.m, 
par_fat.m, par_muscle.m, par_transcripts.m, par_flux.m) 
par_liver.m 
% par_liver.m  
% called by ode_liver.m 
 
function par = par_liver() 
 
k1 = 3;.2;        % GK, gluc -> g6p 
 129 
km1 = 7.7;       %   k1 * gluc /(km1 + gluc) * (1 + (B_ins/kDins)^ep1) 
ep1 = 10; 
k_1 = 4;.2;.1;.2;       % G6Pase, g6p -> gluc 
km_1 = 1.3;      %   k_1 * g6p /(km_1 + g6p) * (1 + (B_glucgn/kDglucgn)^ep9) 
ep9 = 10; 
k2 = 20;        % GS, g6p -> glyc 
km2 = .57;         %   k2 * GSa * g6p / (km2 + g6p) 
k_2 = 20;      % GP, glyc -> g6p 
km_2 = 1.4;        %   k_2 * GPa * glycgn / (km_2 + glycgn) 
k3 = .1;.05;.1;    % g6p -> pep 
km3 = .01;   %   k3 * g6p/(km3+g6p) * (1 + (B_ins/kDins)^ep2) * 
kDglucgn^en1/(kDglucgn^en1 + B_glucgn^en1) 
ep2 = 10; 
en1 = 10; 
k_3 = .3;   % pep -> g6p 
km_3 = .0034;    %   k_3 * pep/(km_3+pep) * (1 + (B_glucgn/kDglucgn)^ep8) * 
kDins^en6/(kDins^en6 + B_ins^en6) 
ep8 = 10; 
en6 = 10; 
k4 = 2;    % pep -> pyr 
km4 = .18;   %   k4 * pep  * (1 + (B_ins/kDins)^ep3) * kDglucgn^en2/(kDglucgn^en2 + 
B_glucgn^en2) * ki13/(ki13 + alan) 
ki13 = 2; 
ep3 = 10; 
en2 = 10; 
k5 = .0;    % LDH, pyr -> lac 
km5 = .03;       % k5 * pyr / (km5 + pyr) 
k_5 = .1;   % LDH, lac -> pyr 
km_5 = .8;       % k_5 * lac / (km_5 + lac) 
k6 = 1;    % PC, pyr -> oa_m 
km6 = 0.22; 
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p2 = 1;     %   k6 * pyr /(km6+pyr)* (1 + p2*acet_m/(kp2 + acet_m)) * (1 + 
(B_glucgn/kDglucgn)^ep4) 
kp2 = 2;      
p7 = 10;    
ep4 = 10; 
k7 = 1;    % PDH, pyr -> acet_m 
ki8 = 2;    %   k7 * pyr / (km7 + pyr) * ki8/(ki8 + acet_m) 
km7 = .0204; 
k8 = .1;    % oa_m, acet_m -> cit 
ki4 = 3;    %   k8 * oa_m * acet_m * ki4/(ki4 + palmCoA) 
k9 = .1;    % cit -> aK 
k10 = .1;   % aK -> malate 
k11 = .6;   % oa_m -> malate 
ep5 = 10;        % k11 * oa_m * (1 + (B_glucgn/kDglucgn)^ep5) 
k_11 = .01;   % malate -> oa_m 
k12 = .6;   % malate -> oa_c 
ep6 = 10;        % k12 * malate * kDins^en4/(kDins^en4 + B_ins^en4)* (1 + 
(B_glucgn/kDglucgn)^ep6) 
en4 = 10; 
k13 = .5;   % PEPCK, oa_c -> pep 
ep7 = 10;    %   k13 * oa_c * (1 + (B_glucgn/kDglucgn)^ep7) * kDins^en5/(kDins^en5 + 
B_ins^en5) 
en5 = 10; 
k14 = .01;   % cit -> acet_c, oa_c 
ep10 = 10;     %  k14 * citrate * (1 + (B_ins/kDins)^ep10) * 
kDglucgn^en7/(kDglucgn^en7 + B_glucgn^en7) 
en7 = 10; 
k15 = .01;   % acet_c -> malonyl 
p1 = 1;     %   k15 * acet_c * (1 + p1*citrate/(kp1 + citrate)) * ki5/(ki5 + palmCoA) 
kp1 = .5;      
ki5 = 1;     
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k16 = .01;   % acet_c, malonyl -> palm 
                 % k16 * acet_c * malonyl^7 
k17 = .01;   % palm -> palmCoA 
ki1 = .1;   %   k17 * palm * ki1/(ki1 + malonyl) 
k18 = .01;   % palmCoA -> acet_m 
ki2 = 1;    %   k18 * palmCoA * ki2/(ki2 + malonyl) 
k19 = .01;   % acet_m -> ket 
ep11 = 10;     %   k19 * acet_m^2 * (1 + (cAMP/kdcAMP)^ep11) * 
kDins^en8/(kDins^en8 + B_ins^en8) 
en8 = 10; 
k20 = .2;   % alan -> pyr, non-ALT pathway 
k21 = .001;    % pyr,glutamate -> alan,aK 
en3 = 10;                % k21 * pyr * glutamate * kDins^en3/(kDins^en3 + B_ins^en3) 
km21p = .4; 
km21g = 4.3; 
k_21 = .2;   % alan,aK -> pyr,glutamate 
                 %  k_21 * alan * aK * acet_m * kDins^en3/(kDins^en3 + B_ins^en3)  
km_21a = 21; 
km_21k = .22; 
k22 = .01;  % glutamate sink 
kc1 = 1;   % cAMP growth due to B_glucgn  
kcm1 = 40*10^(-9); % kc1 * B_glucgn/(kcm1 + B_glucgn) 
kc2 = kc1 * 10^(5.5);   % cAMP decay due to B_ins 
kcm2 = 1*10^(-6); 
% dcAMP = kc1 * B_glucgn/(kcm1 + B_glucgn) ... 
%       - kc2 * B_ins/(kcm2 + B_ins) * cAMP; 
kDins = 1 * 10^(-6); 
kDins2 = .75*10^(-6); 
kDglucgn = 40 * 10^(-9); 
kdcAMP = 1*10^(-5.5); 
 
 132 
par=[k1; km1; k_1; km_1; k2; km2; k_2; km_2; k3; km3; k_3; km_3;  
    k4; km4; k5; km5; k_5; km_5; k6; k7; km7; k8; k9; k10;  
    k11; k_11; k12; k13; k14; k15; k16; k17; k18; k19; k21; k_21; 
    ki1; ki2; ki4; ki5; ki8; ki13; p1; p2; p7;  
    kc1; kc2; kcm1; kcm2; kDins; kDglucgn; kdcAMP; kp1; kp2;  
    ep1; ep2; ep3; ep4; ep5; ep6; ep7; ep8; ep9; ep10; ep11;  
    en1; en2; en3; en4; en5; en6; en7; en8; kDins2; k20; k22; km6; km21p; 




% par_glycogen.m  




k1 = 1.4 *60; % min-1 rate constant for phosphorylation of inhibitor  
k2 = 0.01 *60; % min-1 rate constant for dephosphorylation of inhibitor  
k3 = 20 *60; % min-1 rate constant for phosphorylation of phosphorylase kinase  
k4 = 5 *60; % min-1 rate constant for dephosphorylation of phosphorylase kinase  
k5 = 20 *60; % min-1 rate constant for phosphorylation of Phosphorylase  
k6 = 5 *60; % min-1 rate constant for dephosphorylation of Phosphorylase  
k7 = 20 *60; % min-1 rate constant for phosphorylation of glycogen synthase  
k8 = 0.05 *60; % min-1 rate constant for dephosphorylation of glycogen synthase  
km1 = 5 /1000; % mM for inhibitor phosphorylation  
km2 = 0.7 /1000; % mM for dephosphorylation of Inhibitor-1  
km3 = 0.4 /1000; % mM for Phosphorylation of phosphorylase kinase  
km4 = 1.1 /1000; % mM for dephosphorylation of phosphorylase kinase  
km5 = 10 /1000; % mM for phosphorylation of phosphorylase  
km6 = 5 /1000; % mM for dephosphorylation of phosphorylase  
km7 = 15 /1000; % mM for phosphorylation of glycogen synthase  
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km8 = 0.12 /1000; % mM for dephosphorylation of glycogen synthase  
kd = 0.2 /1000; % dissociation of PP1 and phosphorylated PP1 Inhibitor, and also 
phosphorylase a with synthase PP1 
 
% Total Concentrations 
capkt = 0.25 /1000; % mM total R2C2 
It = 1.8 /1000; % mM total Inhibitor concentration  
kt = 2.5 /1000; % mM total Phosphorylase kinase  
pt = 70 /1000; % mM total Glycogen Phosphorylase  
pt = 80 /1000; % mM total Glycogen Phosphorylase  
st = 3 /1000; % mM total Glycogen synthase  
PP1 = 0.25 /1000; % mM PTPase 1  
PP2A = 0.025 /1000; % mM PTPase 2  
k11 = 0.043 /1000; % mM Dissociation constant of cAMP  
k22 = 0.7 /1000; % mM Dissociation constant of cAMP  
ki = 100 /1000; % mM cAMP inhibition constant  
campt = 10 /1000; % mM maximum cAMP  
kg = 349500 /1000; % mM activation constant of glucose-6-phosphate for synthase PP1 
g6pt = 700 /1000; % mM maximum glucose-6-Phosphate  
kgi = 10000 /1000; % mM activation constant of glucose for phosphorylase phosphatase 
s1 = 100; % a multiplicative factor for glucose-6-phosphate effect on glycogen synthase 
dephosphorylation 
kg2 = 500 /1000; % mM inhibition due to glucose-6-phosphate  
s2 = 0.0010; % a multiplicative factor for glucose effect on phosphorylase phosphatase 
k_a = .001 *60*1000;    % min-1 mM-1 dissociation rate constant for PP1_GPa 
ka = k_a/kd;    % min-1 association rate constant for PP1_GPa 
k_gc1 = 1000 *60*1000^2;           % dissociation rate constant for [R2C(cAMP)2]+[C] 
kgc1 = k_gc1/k11;    % association rate constant for [R2C(cAMP)2]+[C] 
k_gc2 = 1000 *60*1000^2;          % dissociation rate constant for [R2(cAMP)4]+[C] 
kgc2 = k_gc2/k22;    % association rate constant for [R2(cAMP)4]+[C] 
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par = [k1; k2; k3; k4; k5; k6; k7; k8; km1; km2; km3; km4; km5; km6; km7; km8; 




% par_blood.m  
% called by ode_blood.m 
 
function par = par_blood() 
 
% BLOOD 
kf = .5;     % feeding to bloodstream, kf 
Imax = 1.3 * 10^(-6);  
Imin = .7 * 10^(-6); 
k_mIns = 8;  
ni = 10;  
Gmax = 50 * 10^(-9);  
Gmin = 30 * 10^(-9); 
k_mGlgn = 8;  
ng = 10; 
 
% LIVER/BLOOD transport: 
ktL1 = 100;    % gluc <-> B_gluc 
ktL2 = .1;    % B_lac -> lac 
ktL3 = .1;    % ket -> B_ket 
ktL4 = .1;    % %%%%%%%%%%%%%%%%%%%%%  DELETE LATER 
ktL5 = .1;    % B_ffa -> palm 
ktL6 = 1;    % B_alan -> alan 
en10 = 10;          % ktL6 * B_alan * kDins^en10/(kDins^en10 + B_ins^en10) 
 
% FAT/BLOOD transport 
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ktF1 = .01;       % B_gluc -> F_g6p 
ep12 = 10;       %   ktF1 * B_gluc * (1 + B_ins^ep12/(kDins^ep12+B_ins^ep12)) 
ktF3 = .01;      % F_ffa -> B_ffa 
en9 = 20;      %   ktF3 * F_ffa^8 * kDins^en9/(kDins^en9 + B_ins^en9) 
 
% MUSCLE/BLOOD transport 
ktS1 = .01;     % B_gluc -> M_g6p 
ep13 = 10;      %   ktS1 * B_gluc * (1 + B_ins^ep13/(kDins^ep13+B_ins^ep13)) 
ktS2 = 1;     % B_ket -> M_ket 
ktS3 = .01;     % M_lac -> B_lac 
ktS4 = 3;     % M_alan -> B_alan 
en11 = 10;     %  ktS4 * M_alan* kDins^en11/(kDins^en11 + B_ins^en11) 
 
% OUTFLOW of blood concentrations 
kd_all = 0.01; 
kd_Bgluc = kd_all;       % outflow of B_gluc 
kd_Bins = kd_all;       % outflow of B_ins 
kd_Bglucgn = kd_all;       % outflow of B_glucgn 
kd_Bffa = kd_all;       % outflow of B_ffa 
kd_Blac = kd_all;       % outflow of B_lac 
kd_Bket = kd_all;       % outflow of B_ket 
kd_Balan = kd_all;       % outflow of B_alan 
 
k_ins = kd_Bins * Imin; 
k1ins = kd_Bins * (Imax-Imin); 
k_glucgn = kd_Bglucgn * Gmax; 
k1glucgn = kd_Bglucgn * (Gmax-Gmin); 
 
par=[kf; ktL1; ktL2; ktL3; ktL4; ktL5; ktL6; 
    ktF1; ktF3; 
    ktS1; ktS2; ktS3; ktS4; 
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    kd_Bgluc; kd_Bins; kd_Bglucgn; kd_Bffa; 
    kd_Blac; kd_Bket; kd_Balan; 
    k1ins; k_mIns; ni; k1glucgn; k_mGlgn; ng; k_ins; k_glucgn; 




% par_fat.m  
% called by ode_fat.m 
 
function par = par_fat() 
 
kf1 = .1;     % F_g6p -> F_acyl 
ep14 = 10;      %   kf1 * F_g6p * (1 + (B_ins/kDins)^ep14) 
kf3 = .2;     % F_acyl -> F_TG 
ep15 = 10;      %   kf3 * F_acyl * (1 + (B_ins/kDins)^ep15) 
kf4 = .1;     % F_TG -> F_ffa 
en12 = 10;    %   kf4 * F_TG * kDins^en12/(kDins^en12 + B_ins^en12) 
kf5 = .1;     % F_ffa -> F_acyl,   kf5 * F_ffa^3 
 




% par_muscle.m  
% called by ode_muscle.m 
 
function par = par_muscle() 
 
ks1 = .0;       % M_g6p -> M_glyc, ks1 * M_g6p 
ks_1 = .0;      % M_glyc -> M_g6p, ks_1 * M_glycgn 
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ks2 = .02;       % M_g6p -> M_pyr, ks2 * M_g6p 
ks3 = .01;       % M_pyr -> M_lac, ks3 * M_pyr 
ks_3 = .01;       % M_lac -> M_pyr, ks_3 * M_lac 
ks4 = .07;        % M_pyr -> M_alan, ks4 * M_pyr 
ks_4 = 0;      % M_alan -> M_pyr, ks_4 * M_alan * M_ket 
ks5 = .5;        % --> M_alan, ks5 
ks_dket = .01;    % M_ket decay rate constant 
 





% Called by ode_blood.m 
% This file called by ode_liver.m changes the parameter representing a specific enzyme 
% for transcriptional regulation or knockout 
 
function new_par =  
par_transcripts(t,k1,k2,k_2,k3,k4,k5,k_5,k6,k7,k11,k12,k13,k14,k16,k17,k18,k19,trans) 
 
%%  trans vector dictates which transcripts are regulated 
%   0 -> transcript not regulated, 1 -> transcript regulated, 2 -> transcript knocked out 
 
gk = trans(1);     % k1, glucokinase, gluc -> g6p 
gs = trans(2);     % k2, glycogen synthase, g6p -> glyc 
gp = trans(3);     % k_2, glycogen phosphorylase, glyc -> g6p 
pfk = trans(4);    % k3, phosphofuctose kinase, g6p -> pep 
pk = trans(5);     % k4, pyruvate kinase, pep -> pyr 
ldh = trans(6);    % k5, k_5, lactate dehydrogenase, pyr <-> lac 
pc = trans(7);     % k6, pyruvate carboxylase, pyr -> oa_m 
pdh = trans(8);    % k7, pyruvate dehydrogenase, pyr -> acet_m 
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mdh = trans(9);    % k11, k12, malate dehydrogenase, oa_m,c <-> malate 
pepck = trans(10);  % k13, phosphoenolpyruvate carboxylase, oa_c -> pep 
cl = trans(11);     % k14, citrate lyase, cit -> acet_c 
fas = trans(12);    % k16, fatty acid synthase, acet_c,malonyl -> palm 
cpt = trans(13);    % k17, carnitine O-palmitoyltransferase, palm -> palmCoA 
beta_ox = trans(14);     % k18, beta-oxidation, palmCoA -> acet_m 
hmgs = trans(15);   % k19, HMG-synthase, acet_m -> ket 
 
%% initialize vectors for transcipt expression factors 
tp_k1 = [1 1 1];    tp_k2 = [1 1 1];    tp_k_2 = [1 1 1]; 
tp_k3 = [1 1 1];    tp_k4 = [1 1 1];    tp_k5 = [1 1 1]; 
tp_k_5 = [1 1 1];   tp_k6 = [1 1 1];    tp_k7 = [1 1 1]; 
tp_k11 = [1 1 1];   tp_k12 = [1 1 1];   tp_k13 = [1 1 1]; 
tp_k14 = [1 1 1];   tp_k16 = [1 1 1];   tp_k17 = [1 1 1]; 
tp_k18 = [1 1 1];   tp_k19 = [1 1 1]; 
 
%  these values represent the proportion of initial mRNA levels taken from 
%  transcript data 
if gk == 1;    tp_k1 = [ 1 0.606060606 0.787878788 ];   end 
if gs == 1;    tp_k2 = [ 1 1.166666667 1.933333333 ];   end 
if gp == 1;    tp_k_2 = [ 1 0.769230769 0.307692308 ];  end 
if pfk == 1;   tp_k3 = [ 1 0.733333333 0.833333333 ];   end 
if pk == 1;    tp_k4 = [ 1 1 0.3 ];                     end 
if ldh == 1;   tp_k5 = [ 1 0.972222222 1.208333333 ];    tp_k_5 = tp_k5;    end 
if pc == 1;    tp_k6 = [ 1 1.2 1.333333333 ];           end 
if pdh == 1;   tp_k7 = [ 1 0.775 0.725 ];               end 
if mdh == 1;   tp_k11 = [ 1 0.8 0.75 ];    tp_k12 = tp_k11;     end 
if pepck == 1; tp_k13 = [ 1 1.276923077 1.384615385 ];  end 
if cl == 1;    tp_k14 = [ 1 0.74 0.2 ];                 end 
if fas == 1;   tp_k16 = [ 1 0.75 0.3 ];                 end 
if cpt == 1;   tp_k17 = [ 1 1.1 2 ];                    end 
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if beta_ox == 1;    tp_k18 = [ 1 1.5 11.5 ];            end 
if hmgs == 1;  tp_k19 = [ 1 1.105263158 1.368421053 ];  end 
 
% % knockouts 
if gk == 2;    tp_k1 = [ 0 0 0 ];                       end 
if gs == 2;    tp_k2 = [ 0 0 0 ];                       end 
if gp == 2;    tp_k_2 = [ 0 0 0 ];                      end 
if pfk == 2;   tp_k3 = [ 0 0 0 ];                       end 
if pk == 2;    tp_k4 = [ 0 0 0 ];                       end 
if ldh == 2;   tp_k5 = [ 0 0 0 ];    tp_k_5 = tp_k5;    end 
if pc == 2;    tp_k6 = [ 0 0 0 ];                       end 
if pdh == 2;   tp_k7 = [ 0 0 0 ];                       end 
if mdh == 2;   tp_k11 = [ 0 0 0 ];    tp_k12 = tp_k11;  end 
if pepck == 2; tp_k13 = [ 0 0 0 ];                      end 
if cl == 2;    tp_k14 = [ 0 0 0 ];                      end 
if fas == 2;   tp_k16 = [ 0 0 0 ];                      end 
if cpt == 2;   tp_k17 = [ 0 0 0 ];                      end 
if beta_ox == 2;    tp_k18 = [ 0 0 0 ];                 end 
if hmgs == 2;  tp_k19 = [ 0 0 0 ];                      end 
 
%% determine time when regulation occurs 
if t < 420 
    c=1; 
elseif t >= 420 & t < 1020 
    c=2; 
else 
    c=3; 
end 
 
%% multiply rate constant by corresponding vector component depending on 
%% regulation type and time point 
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nk1 = k1 * tp_k1(c);        nk2 = k2 * tp_k2(c); 
nk_2 = k_2 * tp_k_2(c);     nk3 = k3 * tp_k3(c); 
nk4 = k4 * tp_k4(c);        nk5 = k5 * tp_k5(c); 
nk_5 = k_5 * tp_k_5(c);     nk6 = k6 * tp_k6(c); 
nk7 = k7 * tp_k7(c);        nk11 = k11 * tp_k11(c); 
nk12 = k12 * tp_k12(c);     nk13 = k13 * tp_k13(c); 
nk14 = k14 * tp_k14(c);     nk16 = k16 * tp_k16(c); 
nk17 = k17 * tp_k17(c);     nk18 = k18 * tp_k18(c); 
nk19 = k19 * tp_k19(c); 
 
new_par = [nk1; nk2; nk_2; nk3; nk4; nk5; nk_5; nk6; nk7; nk11;  
    nk12; nk13; nk14; nk16; nk17; nk18; nk19]; 
return 
 
C.4 Code for Equations (ode_main.m, ode_liver.m, ode_glycogen.m, 
ode_blood.m, ode_fat.m, ode_muscle.m) 
ode_main.m 
% ode_main.m 
% Called by main.m 
% All ode's are grouped according to tissues.  All are called here in the 
% ode_main.m file and output is returned in one main vector, f 
 
function f = ode_main(t,y,run,trans,mut) 
 
% liver: 
gluc=y(1); g6p=y(2); glycgn=y(3); pep=y(4); pyr=y(5);  
lac=y(6); oa_m=y(7); acet_m=y(8); citrate=y(9); aK=y(10);  
malate=y(11); oa_c=y(12); acet_c=y(13); malonyl=y(14); palm=y(15);  





B_gluc=y(22); B_ins=y(23); B_glucgn=y(24);  




F_g6p=y(30); F_acyl=y(31); F_TG=y(32); F_ffa=y(33); 
 
% muscle: 




PP1=y(40); PP1_GPa=y(41); PKa=y(42); GPa=y(43); GSa=y(44);  
R2C2=y(45); C=y(46); R2_C_cAMP2=y(47); R2_cAMP4=y(48); 
 
% call ode files for each tissue: 
f_liver = 
ode_liver(t,y(1:21),B_gluc,B_ffa,B_ins,B_alan,B_lac,B_glucgn,GSa,GPa,run,trans); 
f_blood = ode_blood(t,y(22:29),gluc,lac,ket,F_ffa,M_alan,M_lac,M_ket,run); 
f_fat = ode_fat(t,y(30:33),B_gluc,B_ins); 
f_muscle = ode_muscle(t,y(34:39),B_gluc,B_ket,B_ins); 
 
% glycogen regulatory circuit ode: 
dcAMP1 = f_liver(19);   % involved in ode_liver.m and ode_glycogen.m, combined on 
line 38 
f_glycogen = ode_glycogen(t,[y(40:48);cAMP],gluc,g6p,mut); 




f_liver(19) = dcAMP1 + dcAMP2; 
 





% Called by ode_main.m 
 
function f = ode_liver(t,y,B_gluc,B_ffa,B_ins,B_alan,B_lac,B_glucgn,GSa,GPa, 
run,trans) 
 
% load parameters/variables: 
par=par_liver(); 
k1=par(1); km1=par(2); k_1=par(3); km_1=par(4); k2=par(5);  
km2=par(6); k_2=par(7); km_2=par(8); k3=par(9); km3=par(10);  
k_3=par(11); km_3=par(12); k4=par(13); km4=par(14); k5=par(15);  
km5=par(16); k_5=par(17); km_5=par(18); k6=par(19); k7=par(20);  
km7=par(21); k8=par(22); k9=par(23); k10=par(24); k11=par(25);  
k_11=par(26); k12=par(27); k13=par(28); k14=par(29); k15=par(30);  
k16=par(31); k17=par(32); k18=par(33); k19=par(34); k21=par(35);  
k_21=par(36); ki1=par(37); ki2=par(38); ki4=par(39); ki5=par(40);  
ki8=par(41); ki13=par(42); p1=par(43); p2=par(44); p7=par(45);  
kc1=par(46); kc2=par(47); kcm1=par(48); kcm2=par(49); kDins=par(50);  
kDglucgn=par(51); kdcAMP=par(52); kp1=par(53); kp2=par(54); ep1=par(55);  
ep2=par(56); ep3=par(57); ep4=par(58); ep5=par(59); ep6=par(60);  
ep7=par(61); ep8=par(62); ep9=par(63); ep10=par(64); ep11=par(65);  
en1=par(66); en2=par(67); en3=par(68); en4=par(69); en5=par(70);  
en6=par(71); en7=par(72); en8=par(73); kDins2=par(74); 
k20=par(75); k22=par(76); km6=par(77); km21p=par(78); 
km21g=par(79); km_21a=par(80); km_21k=par(81); 
 143 
par=par_blood(); 
kf=par(1); ktL1=par(2); ktL2=par(3); ktL3=par(4); ktL4=par(5);  
ktL5=par(6); ktL6=par(7); ktF1=par(8); ktF3=par(9); 
ep13=par(34); en9=par(35); en10=par(36); en11=par(37); 
 
% transcriptional regulation 
    tr_par=par_transcripts(t,k1,k2,k_2,k3,k4,k5,k_5,k6,k7,k11,k12,k13,k14,k16,k17,k18, 
k19,trans); 
    k1 = tr_par(1); k2 = tr_par(2); k_2 = tr_par(3); k3 = tr_par(4); 
    k4 = tr_par(5); k5 = tr_par(6); k_5 = tr_par(7); k6 = tr_par(8); 
    k7 = tr_par(9); k11 = tr_par(10); k12 = tr_par(11); 
    k13 = tr_par(12); k14 = tr_par(13); k16 = tr_par(14); k17 = tr_par(15); 
    k18 = tr_par(16); k19 = tr_par(17); 
 
gluc=y(1); g6p=y(2); glycgn=y(3); pep=y(4); pyr=y(5);  
lac=y(6); oa_m=y(7); acet_m=y(8); citrate=y(9); aK=y(10);  
malate=y(11); oa_c=y(12); acet_c=y(13); malonyl=y(14); palm=y(15);  
palmCoA=y(16); ket=y(17); alan=y(18); cAMP=y(19); glutamate=y(20); 
co2=y(21); 
 
% LIVER ode eqns: 
 
dgluc = ktL1 * (B_gluc - gluc) ...      % gluc transport, B_gluc <-> gluc 
-  k1 * gluc /(km1 + gluc) * (1 + B_ins^ep1/(kDins^ep1+B_ins^ep1)) ...   % gluc -> 
g6p 
      + k_1 * g6p /(km_1 + g6p) * (1 + B_glucgn^ep9/(kDglucgn^ep9+B_glucgn^ep9));       
% g6p -> gluc 
dg6p = k1 * gluc /(km1 + gluc) * (1 + B_ins^ep1/(kDins^ep1+B_ins^ep1)) ...        % gluc  
-> g6p 
     - k_1 * g6p /(km_1 + g6p) * (1 + B_glucgn^ep9/(kDglucgn^ep9+B_glucgn^ep9)) ...         
% g6p -> gluc 
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     - k2 * GSa * g6p / (km2 + g6p) ...         % g6p -> glycgn 
     + k_2 * GPa * glycgn / (km_2 + glycgn) ...     % glycgn -> g6p 
     - k3 * g6p/(km3+g6p) * (1 + B_ins^ep2/(kDins^ep2+B_ins^ep2)) * 
kDglucgn^en1/(kDglucgn^en1 + B_glucgn^en1)  ...         % g6p -> pep 
     + k_3 * pep/(km_3+pep) * (1 + B_glucgn^ep8/(kDglucgn^ep8+B_glucgn^ep8)) *  
kDins2^en6/(kDins2^en6 + B_ins^en6);          % pep -> g6p 
dglycgn = k2 * GSa * g6p / (km2 + g6p) ...         % g6p -> glycgn 
      - k_2 * GPa * glycgn / (km_2 + glycgn);     % glycgn -> g6p 
dpep = 2 * k3 * g6p/(km3+g6p) * (1 + B_ins^ep2/(kDins^ep2+B_ins^ep2)) *  
kDglucgn^en1/(kDglucgn^en1 + B_glucgn^en1) ...        % g6p -> pep 
- 2 * k_3 * pep/(km_3+pep) * (1 + B_glucgn^ep8/(kDglucgn^ep8+B_glucgn^ep8)) * 
kDins2^en6/(kDins2^en6 + B_ins^en6) ...       % pep -> g6p 
- k4 * pep / (km4 + pep) * (1 + B_ins^ep3/(kDins^ep3+B_ins^ep3)) * 
kDglucgn^en2/(kDglucgn^en2 + B_glucgn^en2) * ki13/(ki13 + alan) ... 
+ k13 * oa_c * (1 + B_glucgn^ep7/(kDglucgn^ep7+B_glucgn^ep7)) * 
kDins^en5/(kDins^en5 + B_ins^en5);         % pep carboxylase, oa_c --> pep 
dpyr = k4 * pep / (km4 + pep) * (1 + B_ins^ep3/(kDins^ep3+B_ins^ep3)) *  
kDglucgn^en2/(kDglucgn^en2 + B_glucgn^en2) * ki13/(ki13 + alan) ...        % 
pyruvate kinase, pep -> pyr 
     - k5 * pyr / (km5 + pyr)...        % pyr -> lac 
     + k_5 * lac / (km_5 + lac)...       % lac -> pyr 
     - k6 * pyr / (km6 + pyr) * (1 + p2*acet_m/(kp2 + acet_m)) * (1 +  
B_glucgn^ep4/(kDglucgn^ep4+B_glucgn^ep4)) ...         % pyruvate carboxylase, pyr 
-> oa_m 
- k7 * pyr / (km7 + pyr)  * ki8/(ki8 + acet_m) ...            % pyruvate dehydrogenase, 
pyr -> acet_m 
- k21 ./(km21p + pyr) ./ (km21g + glutamate) * pyr * glutamate * 
kDins^en3/(kDins^en3 + B_ins^en3)  ...           % pyr,glutamate -> alan,aK 
+ k_21 ./(km_21a + alan) ./ (km_21k + aK) * alan * aK * acet_m * 
kDins^en3/(kDins^en3 + B_ins^en3) ...   % alan,aK -> pyr,glutamate 
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+ k20 * alan * kDins2^en3/(kDins2^en3 + B_ins^en3);           % alternate pathway, 
alan -> pyr 
 dlac = k5 * pyr / (km5 + pyr)...        % pyr -> lac 
     - k_5 * lac / (km_5 + lac)...       % lac -> pyr 
     + ktL2 * B_lac;     % lac transport (bl to liv), B_lac --> lac 
doa_m = k6 * pyr / (km6 + pyr) * (1 + p2*acet_m/(kp2 + acet_m)) * (1 +  
B_glucgn^ep4/(kDglucgn^ep4+B_glucgn^ep4)) ...            % pyruvate carboxylase, 
pyr -> oa_m 
- k8 * oa_m * acet_m * ki4/(ki4 + palmCoA) ...  % cit synthase, oa_m + acet_m -> 
citrate 
- k11 * oa_m * (1 + B_glucgn^ep5/(kDglucgn^ep5+B_glucgn^ep5))...              % 
malate dehydrogenase, oa_m -> malate 
      + k_11 * malate;      % malate dehydrogenase, malate -> oa_m 
dacet_m = k7 * pyr / (km7 + pyr) * ki8/(ki8 + acet_m) ...          % pyruvate  
dehydrogenase, pyr -> acet_m 
- k8 * oa_m * acet_m * ki4/(ki4 + palmCoA) ...  % cit synthase, oa_m + acet_m -> 
citrate 
+ 8 * k18 * palmCoA * ki2/(ki2 + malonyl) ...     % beta-oxidation, palmCoA -> 
acet_m 
- 2 * k19 * acet_m^2 * (1 + cAMP^ep11/(kdcAMP^ep11+cAMP^ep11)) * 
kDins^en8/(kDins^en8 + B_ins^en8);         % HMG synthase/lyase, acet_m -> ket 
dcitrate = k8 * oa_m * acet_m * ki4/(ki4 + palmCoA) ... % cit synthase, oa_m + acet_m  
-> citrate 
      - k9 * citrate ...     % parital TCA cycle, citrate -> alpha-K 
      - k14 * citrate * (1 + B_ins^ep10/(kDins^ep10+B_ins^ep10)) *  
kDglucgn^en7/(kDglucgn^en7 + B_glucgn^en7);     % citrate lyase, citrate -> acet_c, 
oa_c 
 
daK = k9 * citrate ...          % parital TCA cycle, citrate -> alpha-K 
    - k10 * aK ...                  % parital TCA cycle, alpha-K -> malate 
    + k21 ./(km21p + pyr) ./ (km21g + glutamate) * pyr * glutamate *  
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kDins^en3/(kDins^en3 + B_ins^en3) ...           % pyr,glutamate -> alan,aK 
- k_21 ./(km_21a + alan) ./ (km_21k + aK) * alan * aK * acet_m * 
kDins^en3/(kDins^en3 + B_ins^en3);   % alan,aK -> pyr,glutamate 
dmalate = k10 * aK ...           % parital TCA cycle, alpha-K -> malate 
+ k11 * oa_m * (1 + B_glucgn^ep5/(kDglucgn^ep5+B_glucgn^ep5))...         % malate 
dehydrogenase, oa_m -> malate 
      - k_11 * malate ...      % malate dehydrogenase, malate -> oa_m 
      - k12 * malate * kDins^en4/(kDins^en4 + B_ins^en4)* (1 +  
B_glucgn^ep6/(kDglucgn^ep6+B_glucgn^ep6));          % malate shuttle/DH, malate  
-> oa_c 
doa_c = k12 * malate * kDins^en4/(kDins^en4 + B_ins^en4) * (1 +  
B_glucgn^ep6/(kDglucgn^ep6+B_glucgn^ep6))...         % malate shuttle/DH, malate  
-> oa_c 
- k13 * oa_c * (1 + B_glucgn^ep7/(kDglucgn^ep7+B_glucgn^ep7)) * 
kDins^en5/(kDins^en5 + B_ins^en5) ...     % pep carboxylase, oa_c --> pep 
+ k14 * citrate * (1 + B_ins^ep10/(kDins^ep10+B_ins^ep10)) * 
kDglucgn^en7/(kDglucgn^en7 + B_glucgn^en7);     % citrate lyase, citrate -> acet_c, 
oa_c 
dacet_c = k14 * citrate * (1 + B_ins^ep10/(kDins^ep10+B_ins^ep10)) *  
kDglucgn^en7/(kDglucgn^en7 + B_glucgn^en7) ...     % citrate lyase, citrate -> 
acet_c, oa_c 
- k15 * acet_c * (1 + p1*citrate/(kp1 + citrate)) * ki5/(ki5 + palmCoA) ...      % acet 
carboxylase, acet_c -> malonyl 
        - k16 * acet_c * malonyl^7;   % fas, acet_c + malonyl -> palm 
dmalonyl = k15 * acet_c * (1 + p1*citrate/(kp1 + citrate)) * ki5/(ki5 + palmCoA) ...     %  
acet carboxylase, acet_c -> malonyl 
         - 7 * k16 * acet_c * malonyl^7;  % fas, acet_c + malonyl -> palm 
dpalm = k16 * acet_c * malonyl^7 ...  % fas, acet_c + malonyl -> palm 
      - k17 * palm * ki1/(ki1 + malonyl) ...          % acyl synth/CPT, palm --> palmCoA 
      + ktL5 * B_ffa;       % palm transport (bl to liv), B_palm -> palm 
dpalmCoA = k17 * palm * ki1/(ki1 + malonyl) ...       % acyl synth/CPT, palm -->  
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palmCoA 
         - k18 * palmCoA * ki2/(ki2 + malonyl);       % beta-oxidation, palmCoA -> acet_m 
dket = k19 * acet_m^2 * (1 + cAMP^ep11/(kdcAMP^ep11+cAMP^ep11)) *  
kDins^en8/(kDins^en8 + B_ins^en8) ...         % HMG synthase/lyase, acet_m -> ket 
     - ktL3 * ket;               % ket transport (liv to bl) ket -> B_ket 
dalan = ktL6 * B_alan * (kDins2)^en10/((kDins2)^en10 + B_ins^en10) ...   % alan  
transport, B_alan -> alan 
+ k21 ./(km21p + pyr) ./ (km21g + glutamate) * pyr * glutamate * 
kDins^en3/(kDins^en3 + B_ins^en3) ...    % pyr,glutamate -> alan,aK 
- k_21 ./(km_21a + alan) ./ (km_21k + aK) * alan * aK * acet_m * 
kDins^en3/(kDins^en3 + B_ins^en3) ...    % alan,aK -> pyr,glutamate 
- k20 * alan * kDins2^en3/(kDins2^en3 + B_ins^en3);           % alternate pathway, 
alan -> pyr 
dcAMP = kc1 * B_glucgn^10/(kcm1^10 + B_glucgn^10) ... 
      - kc2 * B_ins^10/(kcm2^10+B_ins^10) * cAMP; 
dglutamate = - k21 ./(km21p + pyr) ./ (km21g + glutamate) * pyr * glutamate *  
kDins^en3/(kDins^en3 + B_ins^en3) ...           % pyr,glutamate -> alan,aK 
+ k_21 ./(km_21a + alan) ./ (km_21k + aK) * alan * aK * acet_m * 
kDins^en3/(kDins^en3 + B_ins^en3) ...   % alan,aK -> pyr,glutamate 
      - k22 * glutamate; 
dco2 = 0; 
 
f = [dgluc; dg6p; dglycgn; dpep; dpyr; dlac; doa_m; dacet_m; dcitrate;  
    daK; dmalate; doa_c; dacet_c; dmalonyl; dpalm;  










% load parameters/variables: 
par=par_glycogen(); 
kg1=par(1); kg2=par(2); kg3=par(3); kg4=par(4); kg5=par(5); 
kg6=par(6); kg7=par(7); kg8=par(8); kmg1=par(9); kmg2=par(10); 
kmg3=par(11); kmg4=par(12); kmg5=par(13); kmg6=par(14); kmg7=par(15); 
kmg8=par(16); k_a=par(17); ka=par(18); kgc_1=par(19); kgc1=par(20);  
kgc_2=par(21); kgc2=par(22); s1=par(23); kg2=par(24); s2=par(25); 
kgi=par(26); capkt = par(27); kt = par(28); pt = par(29);  
st = par(30); PP1t = par(31); 
PP1=y(1); PP1_GPa=y(2); PKa=y(3); GPa=y(4); GSa=y(5);  
R2C2=y(6); C=y(7); R2_C_cAMP2=y(8); R2_cAMP4=y(9); cAMP=y(10); 
 
if mut == 'ful'    % full Mutalik circuit, cAMP dependent protein kinase 
    kmg5s = kmg5.*(1+s1*g6p./kg2);  
    kmg6s = kmg6./(1+s2*gluc./kgi); 
    kmg7s = kmg7.*(1+s1*g6p./kg2); 
    kmg8s = kmg8./(1+s1*g6p./kg2); 
    Jg1 =  0; 
    Jg2 =  0; 
    Jg3 =  kg3 .* C .* (kt - PKa) ./ (kmg3 + (kt - PKa)); 
    Jg4 =  kg4 .* (PP1 + PP1_GPa) .* PKa ./ (kmg4 + PKa); 
    Jg5 =  kg5 .* PKa .* (pt - GPa) ./ (kmg5s + (pt - GPa)); 
    Jg6 =  kg6 .* (PP1 + PP1_GPa) .* GPa ./ (kmg6s + GPa); 
    Jg7 =  kg7 .* (PKa + C) .* GSa ./ (kmg7s + GSa); 
    Jg8 =  kg8 .* (PP1) .* (st - GSa) ./ (kmg8s + (st - GSa)); 
    Jg9 =  ka .* PP1 .* GPa  -  k_a .* PP1_GPa; 
    Jg10 =  kgc1 * R2C2 .* cAMP.^2 - kgc_1 * R2_C_cAMP2 .* C; 
    Jg11 =  kgc2 * R2_C_cAMP2 .* cAMP.^2 - kgc_2 * R2_cAMP4 .* C; 
elseif mut == 'red'    % reduced glycogen regulatory circuit 
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    kmg5s = kmg5.*(1+s1*g6p./kg2);  
    kmg6s = kmg6./(1+s2*gluc./kgi); 
    kmg7s = kmg7.*(1+s1*g6p./kg2); 
    kmg8s = kmg8./(1+s1*g6p./kg2); 
    kg5s = 40 * kg5;        % Force the reduced model to have the same  
    kg7s = 3500 * kg7;      %   half-max velocity as the full model 
    Jg1 =  0; 
    Jg2 =  0; 
    Jg3 =  0; 
    Jg4 =  0; 
    Jg5 =  kg5s .* cAMP .* (pt - GPa) ./ (kmg5s + (pt - GPa)); 
    Jg6 =  kg6 .* PP1 .* GPa ./ (kmg6s + GPa); 
    Jg7 =  kg7s .* cAMP .* GSa ./ (kmg7s + GSa); 
    Jg8 =  kg8 .* PP1 .* (st - GSa) ./ (kmg8s + (st - GSa)); 
    Jg9 =  0; ka .* PP1 .* GPa  -  k_a .* PP1_GPa; 
    Jg10 =  0; 
    Jg11 =  0; 
end 
 
%% GLYCOGEN ode eqns: 
dPP1 = - Jg9;  
dPP1_GPa = Jg9;  
dPKa = Jg3 - Jg4;  
dGPa = Jg5 - Jg6 - Jg9;  
dGSa = Jg8 - Jg7;  
dR2C2 = - Jg10;  
dC = Jg10 + Jg11;  
dR2_C_cAMP2 = Jg10 - Jg11;  
dR2_cAMP4 = Jg11;  
dcAMP = - 2*Jg10 - 2*Jg11; 
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f = [dPP1; dPP1_GPa; dPKa; dGPa; dGSa;  





% Called by ode_main.m 
 
function f = ode_blood(t,y,gluc,lac,ket,F_ffa,M_alan,M_lac,M_ket,run) 
 
% load parameters/variables: 
par=par_blood(); 
kf=par(1); ktL1=par(2); ktL2=par(3); ktL3=par(4); ktL4=par(5);  
ktL5=par(6); ktL6=par(7); ktF1=par(8); ktF3=par(9); 
ktS1=par(10); ktS2=par(11); ktS3=par(12); ktS4=par(13); 
kd_Bgluc=par(14); kd_Bins=par(15); kd_Bglucgn=par(16); kd_Bffa=par(17); 
kd_Blac=par(18); kd_Bket=par(19); kd_Balan=par(20); 
k1ins=par(21); k_mIns=par(22); ni=par(23); k1glucgn=par(24);  
k_mGlgn=par(25); ng=par(26); k_ins=par(27); k_glucgn=par(28); 
Imax=par(29); Gmax=par(30); Imin=par(31); Gmin=par(32); ep12=par(33); 
ep13=par(34); en9=par(35); en10=par(36); en11=par(37); 
par=par_liver(); 
kDins=par(50); kDglucgn=par(51); kDins2=par(74); 
B_gluc=y(1); B_ins=y(2); B_glucgn=y(3);   
B_ffa=y(4); B_lac=y(5); B_ket=y(6); B_alan=y(7); 
sink=y(8); 
 
% FEEDING pattern: 
if run==1           % constant feeding 
      kfeed = kf; 
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elseif run==2 
    if t<0 
        kfeed = kf;     % constant feeding 
    else 
        u = 0; 
        sd = 1/(kf*sqrt(2*pi));  % gives range of [0,kf] 
        % kfeed = exp(-(.014*t-u).^2./(2.*sd^2))./(sd.*sqrt(2.*pi));  % decrease feeding 
        kfeed = .25*cos(.01*t) + .25;       % oscillatory feeding 
        %kfeed = .25*cos(.005*t) + .25;            % oscillatory feeding 
    end 
end 
 
dB_gluc = kfeed ...        % feeding 
        - ktL1 * (B_gluc - gluc) ...   % gluc transport, B_gluc <-> gluc 
        - ktF1 * B_gluc * (1 + B_ins^ep12/(kDins^ep12+B_ins^ep12)) ...    % transport,  
B_gluc -> F_g6p 
- ktS1 * B_gluc * (1 + B_ins^ep13/(kDins^ep13+B_ins^ep13)) ...    % gluc 
transport, B_gluc -> M_gluc 
        - kd_Bgluc * B_gluc;           % output of B_gluc 
dB_ins = k_ins ...              % basal insulin secretion 
       + k1ins*B_gluc^ni / (k_mIns^ni + B_gluc^ni)...    % pos reg by B_gluc 
       - kd_Bins * B_ins;                                    % insulin decay 
dB_glucgn = k_glucgn - k1glucgn*B_gluc^ng / (k_mGlgn^ng + B_gluc^ng)...     % neg  
reg by gluc 
        - kd_Bglucgn * B_glucgn;                                    % glucgn decay 
dB_ffa = - ktL5 * B_ffa ...         % palm transport (bl to liv), B_ffa -> palm 
+ ktF3 * F_ffa^8 * (kDins2)^en9/(kDins2^en9 + B_ins^en9) ...    % transport, F_ffa 
-> B_ffa 
        - kd_Bffa * B_ffa;          % output of B_ffa         
dB_lac = ktS3 * M_lac ...     % lac transport, mus to blood 
       - ktL2 * B_lac ...     % lac transport (bl to liv), B_lac --> lac 
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       - kd_Blac * B_lac;     % output of B_lac 
dB_ket = ktL3 * ket ...         % ket transport (liv to bl) ket -> B_ket 
       - ktS2 * B_ket ...       % ket transport, blood to mus 
       - kd_Bket * B_ket;       % output of B_ket 
dB_alan = ktS4 * M_alan* (.75.*10^(-6))^en11/((.75.*10^(-6))^en11 + B_ins^en11)...      
% alan transport, M_alan -> B_alan 
- ktL6 * B_alan * (.75.*10^(-6))^en10/((.75.*10^(-6))^en10 + B_ins^en10) ...             
% alan transport, B_alan -> alan 
        - kd_Balan * B_alan;            % output of B_alan 
dsink = 6* kd_Bgluc * B_gluc ...            % output of B_gluc 
       + 16* kd_Bffa * B_ffa ...          % output of B_ffa 
       + 3* kd_Blac * B_lac ...     % output of B_lac 
       + 4* kd_Bket * B_ket ...       % output of B_ket 
       + 3* kd_Balan * B_alan;            % output of B_alan 
    





% Called by ode_main.m 
 
function f = ode_fat(t,y,B_gluc,B_ins) 
 
% load parameters/variables: 
par = par_fat(); 
kf1=par(1); kf3=par(2); kf4=par(3); kf5=par(4); 





ktL5=par(6); ktL6=par(7); ktF1=par(8); ktF3=par(9); 
Imax=par(29); Gmax=par(30); Imin=par(31); Gmin=par(32); ep12=par(33); 
ep13=par(34); en9=par(35); en10=par(36); en11=par(37); 
F_g6p=y(1); F_acyl=y(2); F_TG=y(3); F_ffa=y(4); 
 
dF_g6p = ktF1 * B_gluc * (1 + B_ins^ep12/(kDins^ep12+B_ins^ep12))...       %  
transport, B_gluc -> F_g6p 
- kf1 * F_g6p * (1 + B_ins^ep14/(kDins^ep14+B_ins^ep14));         % F_g6p -> 
F_acyl 
dF_acyl = kf1 * F_g6p * (1 + B_ins^ep14/(kDins^ep14+B_ins^ep14))...        % F_g6p ->  
F_acyl 
- kf3 * F_acyl * (1 + B_ins^ep15/(kDins^ep15+B_ins^ep15))...  % F_glyc3p, 
F_acyl -> F_TG 
        + kf5 * F_ffa^3;         % F_ffa2 -> F_acyl     
dF_TG = kf3 * F_acyl  * (1 + B_ins^ep15/(kDins^ep15+B_ins^ep15))...  % F_glyc3p,  
F_acyl -> F_TG 
- kf4 * F_TG * kDins^en12/(kDins^en12 + B_ins^en12);             % F_TG -> F_glyc, 
F_ffa 
dF_ffa = 0;   % hold fat levels constant 
3* kf4 * F_TG * kDins^en12/(kDins^en12 + B_ins^en12)...          % F_TG -> 
F_glyc, F_ffa 
       - 3 * kf5 * F_ffa^3 ...        % F_ffa2 -> F_acyl 
       - 8 * ktF3 * F_ffa^8 * (.75*10^(-6))^en9/((.75*10^(-6))^en9 + B_ins^en9);         %  
transport, F_ffa2 -> B_ffa 
 







% Called by ode_main.m 
 
function f = ode_muscle(t,y,B_gluc,B_ket,B_ins) 
 
% load parameters/variables: 
par=par_muscle(); 
ks1=par(1); ks_1=par(2); ks2=par(3); ks3=par(4);  





ktS1=par(10); ktS2=par(11); ktS3=par(12); ktS4=par(13); 
ep13=par(34); en9=par(35); en10=par(36); en11=par(37); 
M_g6p=y(1); M_glycgn=y(2); M_pyr=y(3); M_lac=y(4); 
M_ket=y(5); M_alan=y(6); 
 
dM_g6p = ktS1 * B_gluc * (1 + B_ins^ep13/(kDins^ep13+B_ins^ep13)) ...     % gluc  
transport, B_gluc -> M_gluc 
       - ks1 * M_g6p ...       % M_g6p -> M_glycgn 
       + ks_1 * M_glycgn ...   % M_glycgn -> M_g6p 
       - ks2 * M_g6p;          % M_g6p -> M_pyr 
dM_glycgn = ks1 * M_g6p ...     % M_g6p -> M_glycgn 
          - ks_1 * M_glycgn;    % M_glycgn -> M_g6p 
dM_pyr = 2 * ks2 * M_g6p ...    % M_g6p -> M_pyr 
       - ks3 * M_pyr ...        % M_pyr -> M_lac 
       + ks_3 * M_lac ...       % M_lac -> M_pyr 
       - ks4 * M_pyr ...        % M_pyr -> M_alan 
       + ks_4 * M_alan * M_ket;    % M_alan -> M_pyr 
dM_lac = ks3 * M_pyr ...        % M_pyr -> M_lac 
       - ks_3 * M_lac ...       % M_lac -> M_pyr 
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       - ktS3 * M_lac;          % lac transport, mus to blood 
dM_ket = ktS2 * B_ket ...       % ket transport, blood to mus 
       ... - ktS4 * M_alan* M_ket * kis1/(kis1 + (B_ins-Imin)/Imax) ...     % alan transport, 
M_alan -> B_alan 
       - ks_dket * M_ket;       % decay term for M_ket (no other output) 
dM_alan = 0;    % hold alanine levels constant 
        ks5 ...               % --> M_alan 
        + ks4 * M_pyr ...        % M_pyr -> M_alan 
        - ks_4 * M_alan * M_ket...      % M_alan -> M_pyr 
        - ktS4 * M_alan* kDins^en11/(kDins^en11 + B_ins^en11);     % alan transport,  
M_alan -> B_alan 
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